

**QUANTITATIVE DETERMINATION OF
FUMONISIN B₁
IN BIOLOGICAL MATERIAL**

by

LALINI REDDY

**Submitted in partial fulfilment of
the requirements for the degree of**

MASTER OF MEDICAL SCIENCE


**in the
Department of Physiology
University of Natal
Durban**

1999

DECLARATION

This study represents original work by the author and has not been submitted in any form to another University. Where use was made of the work of others it has been duly acknowledged in the text.

The research described in this thesis was carried out under the supervision of Professor M.F.Dutton.



L.REDDY

PUBLICATION AND PRESENTATIONS

PUBLICATION

Title: Serum Fumonisin B₁ Levels in African Black Women with Pre-eclampsia

Authors: Reddy L., Dutton M.F., Chuturgoon A.A., Moodley J. and Moodley D.

Journal: *British Journal of Obstetrics and Gynaecology* (with supervisors)

CONFERENCE PRESENTATION

1. Production, purification and detection of fumonisin B₁ in culture material.
Reddy L., Nair A., Odhav B. and Dutton M.F.
Poster presented at **Biotech SA '97** in January 1997, Grahamstown.
2. HPLC analysis of fumonisin B₁. Reddy L., Dutton MF.
Oral presentation at **Regional SASM/ Biochemistry Conference** in October 1997, Durban.
3. HPLC analysis of fumonisin B₁ in serum.
Reddy L. and Dutton M.F.
Poster presented at **International Conference on Frontiers in Biotechnology** in November 1997, Trivandrum, India.

4. HPLC analysis of serum of pre-eclamptic / eclamptic women for the presence of fumonisin B₁.
Reddy L., Ramsunder K. and Dutton M.F.
Poster presented at **1998 International Symposium on Technology Education in June 1998**, Cape Town.
5. HPLC analysis of serum of pre-eclamptic / eclamptic women for the presence of fumonisin B₁.
Reddy L., Ramsunder K. and Dutton M.F.
Poster presented at **10th Biennial Conference of SASM** in July 1998, Durban.
Conference abstracts published in South African Journal of Science **95**, May 1999.
6. Fumonisin B₁ found in sera of eclamptic women in South Africa. Reddy L., Moodley D., Moodley J. and Dutton M.F.
Poster presented at the **1999 Gordon Research Conference on Mycotoxins and Phycotoxins** in June 1999, Plymouth, U.S.A.

WORKSHOP

Attended the **Satellite Workshop to the Gordon Conference on Detection Methods for Phycotoxins and Mycotoxins** in June 1999, Salsbury Cove, Maine, U.S.A.

SUPPORTING SERVICES

In this research the statistical planning and analyses, and recommendations arising from these analyses, have been done with the support of the Institute for Biostatistics and the Pregnancy Hypertension Unit of the Medical Research Council.

ACKNOWLEDGEMENTS

The author wishes to express her sincere gratitude to the following individuals for their assistance in the preparation of this thesis:

Professor M.F. Dutton, supervisor and Head of the Department, and Mr. A. Chuturgoon, Senior Lecturer, of the Department of Physiology, University of Natal, for their expert guidance and constructive criticism.

Professor J. Moodley and Dr. D. Moodley of the MRC Pregnancy Hypertension Unit, University of Natal, for permission to use sera from the Obstetric clinic at the King Edward VIII Hospital.

Ms. D.R. Naidoo and Dr. B. Odhav, Head and Acting Head of the Dept. of Biological Sciences respectively, ML Sultan Technikon, for their encouragement and the granting of study leave.

My spiritual master (Bhagavan Sri Sathya Sai Baba), parents, husband and two little sons for their support, encouragement and patience throughout this research endeavour.

The FRD for their continued financial support during my research without which it would have been a huge struggle to complete a part-time Masters degree.

Merck NT (PTY) Ltd, especially Gopal Pillay, Shona Gander and Janet Sharp for their prompt assistance when required.

Professor G. Shephard, PROMEC, MRC, Tygerberg, for his kind telephonic assistance.

TABLE OF CONTENTS

INTRODUCTION	1
AIMS AND OBJECTIVES	3
CHAPTER 1	4 - 39
1.0 LITERATURE REVIEW : FUMONISINS AND DISEASE	
1.1 Isolation and Structure of fumonisins	4
1.2 Occurrence of fumonisin B ₁	7
1.3 Production of fumonisins	14
1.3.1 Solid culture	14
1.3.2 Liquid culture	16
1.3.3 Clean-up methods	16
1.4 Analytical methods	17
1.4.1 Thin-layer chromatography (TLC)	17
1.4.2 High-performance liquid chromatography (HPLC)	17
1.4.3 Mass Spectroscopy (MS)	19
1.4.4 Immunoassay (IA)	20
1.4.5 Capillary Electrophoresis (CE)	20
1.5 Pathophysiology of fumonisin intoxication	21
1.5.1 Effects on animals	21
1.5.2 Effects on humans	32
1.5.3 Tissues and cell culture	33
1.5.4 Mode of action	34
1.5.5 Pre-eclampsia and fumonisin	35

CHAPTER 2**40-54****2.0 PRODUCTION OF FUMONISIN B₁**

2.1	Introduction	40
2.2	Materials and methods	41
2.2.1	Preparation of inoculum	41
2.2.2	Reagents and solvents	41
2.2.3	Broth culture and extraction of fumonisin B ₁	41
2.2.4	Maize patty culture of fumonisin B ₁	42
2.2.5	Thin-layer chromatography (TLC)	44
2.3	Results	47
2.3.1	Broth	47
2.3.2	Maize patty culture	47
2.4	Discussion	54

CHAPTER 3**56 - 81****3.0 QUANTITATION OF FUMONISIN B₁**

3.1	Introduction	56
3.2	Method and materials	57
3.2.1	High-performance liquid chromatography (HPLC) methodology	57
3.2.2	HPLC of fumonisin B ₁ with OPA derivatisation	65
3.2.3	HPLC analysis of fumonisin B ₁ with FITC derivatiation	68
3.2.4	Capillary electrophoresis (CE) methodology	70
3.2.5	Capillary electrophoresis (CE) of FB ₁	70
3.3	Results	72
3.3.1	Chromatography of FB ₁ standards	72
3.3.2	Quantitation of FB ₁ in broth culture	77

3.3.3	Quantitation of FB ₁ in patty culture	79
3.4	Discussion	79
3.4.1	Development of methods of analysis for fumonisin B ₁	79
3.4.2	Yield of FB ₁ in broth culture	81
3.4.3	Yield of FB ₁ in patty culture	81

CHAPTER 4

82 - 102

4.0 HIGH-PERFORMANCE LIQUID CHROMATOGRAPHY

ANALYSIS OF SERUM OF PRE-ECLAMPTIC WOMEN FOR THE PRESENCE OF FUMONISIN B₁

4.1	Introduction	82
4.2	Method	85
4.2.1	Study population and sample collection	85
4.2.2	Extraction and clean up of serum	85
4.2.3	Derivatisation and HPLC analysis	86
4.2.4	Recovery by Bond-elut SAX columns	88
4.2.5	Verification of FB ₁ by immunoaffinity columns	88
4.2.6	Verification of the presence of FB ₁ in serum by mass spectroscopy	89
4.2.7	Statistical tests	90
4.3	Results	90
4.4	Discussion	99
4.5	Conclusion	102

SUMMARY	103
----------------	-----

APPENDIX 1	104
-------------------	-----

APPENDIX 2	105
-------------------	-----

REFERENCES	106-126
-------------------	---------

LIST OF TABLES

	PAGE
Table 1. Occurrence of FB ₁ in foods and feeds worldwide	9
Table 2. Pathophysiological effects common to pre-eclampsia /eclampsia and animals fumonosis (F)	37
Table 3. Fumonisin B ₁ standards quantitated on HPLC using OPA derivatization	74
Table 4. Comparison of sensitivity of various procedures used to quantitate fumonisin	77
Table 5. Obstetric and epidemiological characteristics of the three groups of women tested - mean (SE).	91
Table 6. Concentration of FB ₁ in the 3 groups of sera tested (μg/ml)	94
Table 7. Comparison of clean up procedures of FB ₁ from sera	95
Table 8. Clinical data of serum samples tested on Mass Spectroscopy	95

LIST OF FIGURES

	PAGE
Figure 1. Structures of the fumonisins B ₁ and sphingosine	6
Figure 2. Maize cobs contaminated with a fungus which produces toxic fumonisins.	8
Figure 3. Toxic fumonisins cause liquefaction of the brain cells of animals resulting in the fatal hole-in-the-head disease	23
Figure 4. Amberlite IRA beads used to clean-up <i>F. moniliforme</i> broth culture.	43
Figure 5. Using the Bond Elut / Vac Elut™ System	45
Figure 6. Broth Cultures of <i>Fusarium moniliforme</i> PPR1 1059 after 17 days	48
Figure 7. TLC analysis of broth culture fractions eluted from amberlite after 28 days	49
Figure 8. Patty culture of <i>F. moniliforme</i> PPR1 1059 at 26 °C after 14 days	51
Figure 9. <i>F. moniliforme</i> PPR1 1059 on Sabourand agar at 26 °C after 1 week	52
Figure 10. TLC analysis of maize patty culture (A-N) after clean-up with Bond-elut cartridges with R _f values ranging from 0.50 to 0.53	53
Figure 11. A representation of the components of an HPLC system	58
Figure 12. Lachrom HPLC (Merck NT) used for quantitation of FB ₁	66
Figure 13. Basic configuration of the P/ACE Capillary Electrophoresis System	71
Figure 14. Chromatograms of OPA derivatization of FB ₁ standards	73
Figure 15. Standard curve of OPA derivatised FB ₁ .	75
Figure 16. Chromatograms of FITC derivatised FB ₁ standards	76
Figure 17. HPL chromatogram of FB ₁ produced in broth culture after 28 days	78
Figure 18. Chromatogram of maize patty culture (5g) showing presence of FB ₁	80
Figure 19. Solid-phase extraction (Bond-elut) of fumonisin from serum	87
Figure 20. HPL chromatograms showing presence of FB ₁ and HFB ₁	92
Figure 21. ESI mass spectrum of FB ₁	96
Figure 22. ESI mass spectrum of serum of a pregnant woman	97
Figure 23. Fumonisin B ₁ concentration in sera of pregnant woman	98

ABSTRACT

The mycotoxin, fumonisin B₁ is produced by the mould *Fusarium moniliforme*, a common contaminant of maize and maize products. Small doses (mg/kg) of ingested fumonisin B₁ have been shown to cause diseases and even death in animals, including non-human primates. Thus highly sensitive methods have been employed to detect fumonisin B₁ presence in foods, feeds and in animals. This study comprised two parts. The initial part focussed on establishing reliable extraction, purification and quantitation of fumonisin B₁ using high-performance liquid chromatography (HPLC) on culture extracts. The second part was to analyse sera of Black African women with pre-eclampsia for the presence of fumonisin B₁ using HPLC.

Maize patty cultures and broth cultures were inoculated with *Fusarium moniliforme* PPRI 1059 and incubated. Fumonisin B₁ was extracted and purified by centrifugation strong anion exchange chromatography (SAX). Eluents from SAX cartridges were analysed using Thin - layer chromatography (TLC) and fluorescence HPLC after o-phthalaldehyde (OPA) derivatisation. Fumonisin B₁ standards on HPLC gave a retention time of 7.5 minutes using methanol /0.1 M sodium dihydrogen phosphate (68 + 32, pH 3.3) as mobile phase and a 25 cm C8 column. Patty cultures produced the highest yields of fumonisin B₁. In the case of serum samples, a double-blind study was carried out using women attending the obstetric clinic at a large city teaching hospital. The population comprised normal, pre-eclamptic and eclamptic women. On HPLC analysis a significantly higher mean concentration of fumonisin B₁ concentration was found in the eclamptic group ($P < 0,005$) as compared to the other two groups. Thus fumonisin B₁ may have a role to play in eclampsia for which the aetiology is still unknown.

INTRODUCTION

The world is plagued with various types of contaminations. There are physical, chemical, microbiological, emotional and many other types of contaminating agents or processes. These affect us to some degree or other in our daily lives. One such contamination, is mycotoxins, an example being fumonisin B₁ (FB₁), which is produced by the mould *Fusarium moniliforme* (Sheldon) (Gelderblom *et al.*, 1988.). This mould commonly contaminates maize, maize products and various other foods and feeds worldwide (Doko *et al.*, 1995, Sydenham *et al.*, 1991, Yoshizawa *et al.*, 1994, Fazekas and Toth 1995, Murphy *et al.*, 1993). Thus people and animals who consume maize frequently are at high risk of fumonisin intoxication (Bondy *et al.*, 1995; Campbell, 1996; Espada *et al.*, 1994; Marasas *et al.*, 1993).

Animal studies have already shown this toxin to cause serious animal diseases, such as hole-in-the-head disease or equine-leucoencephalomalacia (ELEM) in horses (Marasas *et al.*, 1988, Kellerman *et al.*, 1990, Pellegrin *et al.*, 1990), pulmonary oedema in pigs (Gelderblom *et al.*, 1992, Mirocha *et al.*, 1992, Colvin and Harrison, 1992) and hepatocarcinoma in rats (Gelderblom *et al.*, 1992). Epidemiological studies have suggested that fumonisins may be partially responsible for the high incidence of oesophageal cancer (OC) in the Transkei region of South Africa (Sydenham *et al.*, 1991, Rheeder *et al.*, 1992).

The fumonisins are long hydroxylated hydrocarbon chains with an amino group and two tricarboxylic acid groups attached via ester bonds (Caldas *et al.*, 1995). The latter groups make fumonisins water soluble but insoluble in non-polar organic solvents. Thus, although production of fumonisins in culture media by *Fusarium* spp. is somewhat simple,

extraction and purification of the toxin is tedious (Cawood *et al.*, 1991). Many authors relate the problems encountered with regard to the production, extraction and purification of fumonisins in solid and liquid cultures. Fumonisin found in foods, feeds and culture material may occur in relatively low levels ($\mu\text{g}/\text{kg}$). Thus sensitive analytical techniques, such as high-performance liquid chromatography (HPLC) (Thiel *et al.*, 1993) and enzyme-linked immunoassay (Schneider *et al.*, 1995), are being used to detect and quantitate fumonisins in biological material.

The fumonisin molecule shows a strong structural resemblance to the phospholipid, sphingosine (Wang *et al.*, 1991) and has been found to disrupt sphingolipid biosynthesis (Shephard *et al.*, 1996). This could result in numerous pathophysiological effects in animals including man (Brown *et al.*, 1996; Reddy *et al.*, 1996; Bondy *et al.*, 1997).

Fumonisin have been shown to produce many serious pathological effects in many different animals, animal and human cell lines, plants and microorganisms that have been experimentally injected with the toxin. A thorough literature search has shown that many of the symptoms produced in animals by fumonisin are similar to that of a disease in pregnancy, called pre-eclampsia (current study). Some of these symptoms are pulmonary oedema, cerebral oedema, foetal malformations and liver and kidney damage.

AIMS AND OBJECTIVES

1. Production of FB₁ standard.
2. Setting up of suitable and sensitive analytical procedures for the quantitation of FB₁.
3. Analysis of serum from patients with pre-eclampsia for the presence of FB₁ using HPLC.

CHAPTER 1

1.0 LITERATURE REVIEW : FUMONISINS AND DISEASE

1.1 Isolation and Structure of Fumonisin

Fumonisin are a group of mycotoxins (poisonous secondary metabolites of fungi) that are produced by the mould *Fusarium*. The toxins were originally isolated from *Fusarium moniliforme* MRC 826 by the Programme on Mycotoxins and Experimental Carcinogenesis (PROMEC) group of South African researchers directed by Professor WFO Marasas (Bezuidenhout *et al.*, 1988; Gelderblom *et al.*, 1988). Fumonisin was also isolated from Transkeian maize cultures and designated fumonisin B₁ (FB₁) (Laurent *et al.*, 1989; Haschek *et al.*, 1992). Today *F. moniliforme* remains the most important producer of FB₁ followed by *F. proliferatum*, *F. nygamai* and *F. napiforme* (Nelson *et al.*, 1992), probably because of their association with maize and millet. Other species that produce the toxin are *F. subglutinans*, *F. anthophilum*, *F. dlamini*, *F. oxysporum* var *redolens*, *F. polyphialidicum*, *F. globosum* and *Alternaria alternata* (Thiel *et al.*, 1991; Norred *et al.*, 1993; Bullerman and Tsai, 1994; Abbas and Ocam, 1995; Seo and Lee, 1996; Sydenham *et al.*, 1997).

To date, seven forms of fumonisins have been discovered, namely, fumonisin B₁ (FB₁), B₂, B₃, B₄, A₁, A₂ and C₁ (Wilkes and Sutherland, 1998). Their structures are based on a 20 carbon hydroxylated hydrocarbon chain (pentahydroxycosane) with two hydroxyls esterified to two propane- 1,2,3-tricarboxylic acid molecules and an amino group at one

end (Fig.1) (Dutton,1996; Gelderblom *et al.*,1992; Poche *et al.*, 1994; Badria *et al.*, 1995; Wilkes and Sutherland, 1998). The molecular formula is $C_{34}H_{59}NO_{15}$ with a molecular weight of 721D.

Structural and purity verification of fumonisins have been possible with nuclear magnetic resonance (NMR) spectroscopy (Bezuidenhout *et al.*,1988). Fumonisin B₁ differs from B₂ in that it has an extra hydroxyl at position 10. A stereochemical model of fumonisins (Beier and Stanker, 1997) shows a globular cage-like feature of the backbone and acid side-chains of FB₁ and FB₂ which suggest their potential as chelators. Their exposed surfaces were found to be hydrophobic. Gas chromatography-mass spectrometry (GC-MS) experiments indicate that alanine, a precursor in the biosynthesis of FB₁, is directly incorporated into FB₁ at C-1 and C-2 (Fig.1) (Branham and Plattner, 1993; Melcion and Richard-Molard, 1997; Plattner and Shackleford, 1992).

Fumonisin are hydrolysed on heating with 6 M HCl or 0.05 - 2 M KOH bringing about the removal of the two tricarballic acid R groups (Fig.1) leaving the corresponding aminopentol (Jackson and Bennett, 1990; Sydenham *et al.*, 1995). Another toxin showing a similar chemical structure is the AAL toxin which is produced by the *Alternaria* spp. (Boyle and Kishi, 1995).




Fig.1 Structure of fumonisin B₁ and sphingosine (*Wang 1992*)

1.2 Occurrence of Fumonisin B₁

The most common food contaminated by *Fusarium* spp. is maize and it is here that the toxin is produced under certain host stresses, such as drought followed by heavy rains and damage by insects (Vleggaar, 1989) (Fig. 2). The fungus however grows endophytically and shows no symptoms for quite a while. Thus although the maize may appear healthy it may possess minute, though sufficient toxin to cause pathological damage to consumers.

The toxin has also been found to occur in other foods like rice, oats and sorghum (Dawlatana *et al.*, 1995; Sydenham *et al.*, 1992A; Doko *et al.*, 1995). Contaminated maize is often used as animal feed and thus feed is an indirect source of fumonisins (Sanchis *et al.*, 1995, Ueno *et al.*, 1993). Fumonisin has been found to co-occur with zearalenone and deoxynivalenol, two other mycotoxins produced by *Fusarium* spp., in the maize of Transkei (Marasas *et al.*, 1979).

Maize and maize-based foods and feeds contaminated by fumonisin B₁ ($\mu\text{g}/\text{kg}$) worldwide are summarised in Table 1. Healthy maize is that which was destined for human consumption and was found to contain an average concentration of FB₁ ranging from 80 to 2 380 $\mu\text{g}/\text{kg}$ (Sydenham *et al.*, 1990, 1991; Rheeder *et al.*, 1992; Sanchis *et al.*, 1994). Plain maize (maize samples in general) was found to contain FB₁ with levels ranging from 40 to 3 500 $\mu\text{g}/\text{kg}$ in fifteen studies carried out (Bhat *et al.*, 1997; Shetty *et al.*, 1997; Patel *et al.*, 1997). Maize meal was also extensively studied, being the diet staple of many countries. A particular type of maize meal found in the USA, blue maize meal, was found to contain the highest level of fumonisins at a level of 8 484 $\mu\text{g}/\text{kg}$ (Pestka *et al.*, 1994).




Fig. 2 Maize cobs contaminated with a fungus which produces toxic fumonisins. A toxin responsible for hole-in-the-head disease in horses and donkeys was isolated.

(Vleggar 1989)

Other maize meal had fumonisins ranging from 50 to 5 824 $\mu\text{g/kg}$ (Doko *et al.*, 1995; Sydenham *et al.*, 1991). Maize rice (grits), tortilla and popcorn were found to contain a similar FB_1 concentration with a maximum of 1 410 $\mu\text{g/kg}$ (Ueno *et al.*, 1993; Pittet *et al.*, 1992). However, three out of four studies showed that cornflakes, corn noodles and corn cookies contain no FB_1 (Sydenham *et al.*, 1991). This is perhaps to be expected as these products are dry heat-processed (Dupuy *et al.*, 1993; Jackson *et al.*, 1997). One study carried out on puffed maize, which is processed differently, gave a relatively high level of FB_1 , namely, 61 000 $\mu\text{g/kg}$ (Doko and Visconti, 1994). Canned sweet corn contained 235 $\mu\text{g/kg}$ and frozen sweet corn gave a higher concentration (Trucksess *et al.*, 1995).

Table 1. Occurrence of FB_1 in foods and feeds worldwide.

COMMODITY	COUNTRY	AVERAGE CONC. $\mu\text{g/kg}$ (parts/billion)	REFERENCE
FOODS			
Maize			
healthy	Egypt	2 380	Sydenham <i>et al.</i> , 1991
	Egypt	+ ve	Allah, 1998
	Transkei	1 600	Sydenham <i>et al.</i> , 1990
	Transkei	1 530	Rheeder <i>et al.</i> , 1992
	USA	1 048	Sydenham <i>et al.</i> , 1991
	Spain	80	Sanchis <i>et al.</i> , 1994
flour	China	100	Ueno <i>et al.</i> , 1993

plain maize	China	+ ve	Yoshizawa <i>et al.</i> , 1994
	-	+ ve	Bhat <i>et al.</i> , 1997
	India	+ ve	Shetty <i>et al.</i> , 1997
	Southeast Asia	+ ve	Yamashita <i>et al.</i> , 1995
	European countr.	3 500	Doko <i>et al.</i> , 1995
	Pol,Rum.,Croat.	40	Doko <i>et al.</i> , 1995
	USA	+ ve	Patel <i>et al.</i> , 1997
	Zambia	1 710	Doko <i>et al.</i> , 1995
	Italy	2 250	Logrieco <i>et al.</i> , 1995
	South Africa	+ ve	Dutton <i>et al.</i> , 1993
	Poland	+ ve	Chelkowski <i>et al.</i> , 1995
	Uruguay	+ ve	Pineiro <i>et al.</i> , 1997
	Italy	+ ve	Ritieni <i>et al.</i> , 1997
	Taiwan	+ ve	Tseng and Liu, 1997
	Transkei	1 990	Rheeder <i>et al.</i> , 1992
	Transkei	563	Vesonder <i>et al.</i> , 1990
meal (blue)	USA	8 484	Pestka <i>et al.</i> , 1994
meal (yellow)	USA	5 824	Pestka <i>et al.</i> , 1994
	USA	1 050	Sydenham <i>et al.</i> , 1990
	-	910	Stack and Eppley, 1992
	Zimbabwe	740	Doko <i>et al.</i> , 1995
	Peru	660	Sydenham <i>et al.</i> , 1991
	Canada	50	Sydenham <i>et al.</i> , 1991
	Switzerland	85	Pittet <i>et al.</i> , 1992
	South Africa	138	Sydenham <i>et al.</i> , 1991
rice (grits)	Japan	500	Ueno <i>et al.</i> , 1993
	Switzerland	260	Pittet <i>et al.</i> , 1992

	USA	1 048	Sydenham <i>et al.</i> , 1991
cornflakes	USA	0	Sydenham <i>et al.</i> , 1991
	USA	27	Pestka <i>et al.</i> , 1994
	Switzerland	55	Pittet <i>et al.</i> , 1992
tortilla /popcorn	USA	1 410	Hopmans <i>et al.</i> , 1993
	USA	500	Pestka <i>et al.</i> , 1994
corn cookie/ noodle	Switzerland	0	Pittet <i>et al.</i> , 1992
commercial foods	USA	635	Sydenham <i>et al.</i> , 1991
	USA	+ ve	Rumbeiha <i>et al.</i> , 1997
puffed maize	Italy	61 000	Doko and Visconti, 1994
sweet corn	Switzerland	70	Pittet <i>et al.</i> , 1992
(frozen)	USA	350	Trucksess <i>et al.</i> , 1995
(canned)	USA	235	Trucksess <i>et al.</i> , 1995
screenings	USA	37 900	Murphy <i>et al.</i> , 1993
bran	USA	0	Pestka <i>et al.</i> , 1994
	Taiwan	2 500	Tseng and Liu, 1997
	-	200	Stack and Eppley, 1992
	-	+ ve	Katta <i>et al.</i> , 1997
kernels	Moz, Bots,Mal.	20	Doko <i>et al.</i> , 1995
	China	6 800	Ueno <i>et al.</i> , 1993
	Switzerland	+ ve	Dowling <i>et al.</i> , 1997
	USA,SA,Argent.	1 600	Ueno <i>et al.</i> , 1993
seeds	France	5 000	Logrieco <i>et al.</i> , 1995
pre-harvest (earrot)	Sardinia	250 000	Bottalico <i>et al.</i> , 1995

farm stored	Honduras	3 000	Julian <i>et al.</i> , 1995
mouldy	Hungary	16 735	Fazekas and Tothe, 1995
Oats (black)	Brazil	+ ve	Sydenham <i>et al.</i> , 1992A
Rice	-	5 000	Dawlatana <i>et al.</i> , 1995
	-	+ ve	Desjardin <i>et al.</i> , 1997
Wheat	Poland	+ ve	Chelkowski <i>et al.</i> , 1995
Barley	Poland	+ ve	Chelskowski <i>et al.</i> , 1995
Rye	Egypt	+ ve	Fadl-Allah <i>et al.</i> , 1997
Sorghum (mouldy)	Bots/Malawi	20	Doko <i>et al.</i> , 1995
	-	+ ve	Bhat <i>et al.</i> , 1997
	Korea	650	Soo <i>et al.</i> , 1994
	India	+ ve	Shetty <i>et al.</i> , 1997
Millet	Korea	650	Soo <i>et al.</i> , 1994
Milk	USA	< 5 ng/ml	Maragos and Richard, 1994
	-	+ ve	Hammer <i>et al.</i> , 1996
FEEDS			
Forage grass	New Zealand	+ ve	Mirocha <i>et al.</i> , 1992
Mouldy maize	Transkei	29 300	Sydenham <i>et al.</i> , 1990
	Transkei	53 740	Rheeder <i>et al.</i> , 1992
Feed	USA	12 100	Price <i>et al.</i> , 1993
(ELEM)	USA	632 462	Sydenham <i>et al.</i> , 1992A
	Brazil	19 000	Sydenham <i>et al.</i> , 1992A
(poultry) (rodent)	Switzerland	235	Pittet <i>et al.</i> , 1992
	India	+ ve	Shetty <i>et al.</i> , 1997
	-	+ ve	Churchwell <i>et al.</i> , 1997

	Spain	400	Sanchis <i>et al.</i> , 1995
Gluten-based	USA, unknown	1 100	Ueno <i>et al.</i> , 1993
Dog/cat food	USA	859	Hopmans <i>et al.</i> , 1993
Maize kernels	Korea	506	Soo <i>et al.</i> , 1994

Maize screenings after sieving gave a high level of toxin 37 900 $\mu\text{g/kg}$ (Murphy *et al.*, 1993). Toxin levels in bran ranged from 0 to 2 500 $\mu\text{g/kg}$ (Pestka *et al.*, 1994). Maize kernels in Africa and the Far East gave levels ranging from 20 to 1600 $\mu\text{g/kg}$ (Doko *et al.*, 1995 ; Ueno *et al.*, 1993). Maize seeds tested in France (Logrieco *et al.*, 1995) gave a concentration of 5 000 $\mu\text{g/kg}$ fumonisins. Ear rot pre-harvest maize had a very high level of FB₁ (250 000 $\mu\text{g/kg}$). Farm stored maize had 3 000 $\mu\text{g/kg}$ fumonisins and mouldy maize had 16 735 $\mu\text{g/kg}$ fumonisins. Other foods that contained FB₁ were black oats, rice, wheat, barley, sorghum and millet with FB₁ levels 20 to 5000 $\mu\text{g/kg}$ (Sydenham *et al.*, 1992A; Dawlatana *et al.*, 1995; Chelkowski *et al.*, 1995; Doko *et al.*, 1995; Soo *et al.*, 1994) . Sorghum and maize are used in the making of traditional beer and the toxin is often transferred to the beer (Marasas *et al.*, 1993). Milk showed negligible levels of toxin (< 5 ng/ml) derived from cows fed fumonisin contaminated feed (Maragos and Richard, 1994). Feeds were also extensively surveyed and fumonisins were found in relatively high levels with a maximum of 632 462 $\mu\text{g/kg}$. Gluten-based foods had 1 100 $\mu\text{g/kg}$ FB₁. Fumonisins were also found in dog and cat food (859 $\mu\text{g/kg}$).

Fumonisins, unlike most other mycotoxins, are not restricted to certain countries. They were found in all continents of the world thus indicating that their prevalence is not climate dependant (Table 1). Egypt and the European countries showed high levels of the toxin in healthy and plain maize (Sydenham *et al.*, 1991; Doko *et al.*, 1995). Blue and yellow

maize meal, maize rice and tortilla showed highest levels of fumonisins in the USA. Puffed maize had a high level of the toxin in Italy. The USA showed very high levels of toxin in maize screenings confirming their possible presence in maize based foods. The Far East countries had high levels of toxin in maize kernels (Ueno *et al.*, 1993). Studies of maize from the Transkei by Sydenham *et al.* (1990), where ELEM was found to occur showed the highest level of FB₁ in plain maize (Rheeder *et al.*, 1992). In Sardinia ear-rot maize showed an extremely high level of the toxin (Bottalico *et al.*, 1995). Farm stored maize in Honduras showed high levels of toxin. Pittet *et al.* (1992) in Switzerland found the highest levels of FB₁ in his country to be in maize rice. Of the many African countries, from which Doko *et al.* (1995) analysed maize, he found that Zimbabwe showed the highest level of fumonisins in maize meal. In Hungary high levels of toxin was found in mouldy maize (Fazekas and Toth, 1995). Feeds showed extremely high levels of toxin in the USA, Transkei and Brazil.

1.3 Production of Fumonisins

1.3.1 Solid culture

Fumonisins can be readily produced by strains of *F. moniliforme*, *F. proliferatum* and related species on autoclaved maize kernels (Nelson *et al.*, 1992). For large-scale production, 500 g of yellow maize kernels and 500 ml of distilled water are added to a 30.5 x 61 cm autoclavable polyethylene bag. An autoclavable bag would avoid contamination of kernels during transfer to another container. The maize is inoculated by drawing an aqueous suspension from a lyophilised culture (*F. moniliforme*) into a sterile 5 ml syringe fitted with a 19-gauge needle and injecting 1 ml through the side of each bag.

Bags of inoculated maize are incubated in the dark at 20 to 22 °C in a closed cupboard for four weeks. Seven to eight days after inoculation, holes are punched near the tops of the bags to promote aeration. After the incubation period, cultures are soaked overnight in chloroform/ acetone (50/50, v/v) in 4-litre flasks to kill the fungus. This process is followed by filtering through 1 mm nylon mesh screens and air drying the culture material for 24 to 48 hours. The most important factors in the production of fumonisins in bulk maize cultures are temperature control, moisture and aeration using a shaking incubator. By this method yields of 2-4 g fumonisins per kg of culture material can be routinely obtained (Nelson *et al.*, 1992, 1993). Cracked maize is also used to produce fumonisins, but may be problematic in that the clumping of maize in culture may prevent uniform distribution of inoculum and thereby lead to reduced concentrations of toxin being produced.

The biosynthesis of mycotoxin labelled with ^{14}C methionine by *Fusarium* spp. has been carried out with both solid and liquid media. Although production of mycotoxins is much higher in solid media, isotopic labeling in solid media yields compounds with low specific activities (Alberts *et al.*, 1993A). The production of fumonisins in solid maize culture begins after 14 days whereas it takes only 3 days for toxin to be produced in liquid culture. This is too long for specific incorporation of precursors. The kinetics of growth and production of fumonisin by *F. moniliforme* MRC 826 in maize patty cultures were investigated (Alberts *et al.*, 1993A). Production time was reduced to 2 days. Incorporation of the isotope was enhanced by adding 50 mg of unlabelled L- methionine and 200 μCi of L- methyl ^{14}C methionine to a 30 g maize patty over 9 days yielding a specific activity of 36 μCi / mmol.

1.3.2 Liquid culture

Early studies of liquid culture of *Fusarium* spp. produced lower yields of fumonisins than solid culture. *Fusarium proliferatum* gives better yields of fumonisins in liquid culture. More recently, fumonisins have been produced in 10 litre stirred liquid cultures, where yields comparable to solid culture were claimed with simpler extraction and clean-up procedures (Miller *et al.*, 1994). Ion-exchange chromatography using a DEAE Sephadex column was carried out to extract fumonisins from filtered broth. The toxin was then purified on a silica gel column. Various liquid culture media using different carbon sources were also investigated since they are metabolised by micro-organisms during growth via the glycolytic pathway and Krebs tricarboxylic acid cycle to acetate, a precursor of fumonisin biosynthesis (Alberts *et al.*, 1994). Optimal fungal growth and production of fumonisins were obtained in medium A, B, and C primarily containing glucose, sucrose and galactose respectively.

1.3.3 Clean-up methods

Extraction and purification of fumonisins can be unexpectedly difficult and time consuming. Fumonisins contain a free primary amine and multiple free carboxyl groups that can carry positive and negative charges. Subtle changes in pH or ionic strength in the complex extracts from which they are purified can sometimes affect chromatographic behaviour. A common solvent mixture used for extraction of fumonisins from maize is methanol/ water (3:1). The PROMEC group of researchers and others carry out sample preparation for HPLC analysis of FB₁ with the Bond-elut strong anion exchange (SAX)

column (Shephard *et al.*, 1990; Scott and Lawrence, 1994). An alternative method of extraction uses the C18 Sep-Pak Vac (SAX) columns (Holcomb *et al.*, 1993) or the Fumonitest immunoaffinity columns.

1.4 Analytical Methods

1.4.1 Thin-layer chromatography (TLC)

Many TLC systems have been developed for qualitative analysis of fumonisins.

Ackerman's (1991) systems are the most widely used with chloroform/ methanol/ acetic acid (60:35:10) run on normal phase silica with visualisation accomplished by acidic anisaldehyde reagent, because of a lack of a suitable chromophore in the molecule.

Another TLC method by Rottinghaus *et al.* (1992), used methanol/ 4% KCl (3:2) as mobile phase on a Whatman LKC18-K reverse phase TLC plate. High-performance TLC (HPTLC) in normal phase was also carried out for quantitative determination of fumonisin in rice (Dawlatana *et al.*, 1995).

1.4.2 High-performance liquid chromatography (HPLC)

The fumonisins do not absorb UV or visible light, nor do they fluoresce, thus fumonisin must be derivatised for detection purposes. Many derivatising agents have been used to improve detection and quantitation of fumonisins, but with varying degrees of efficiency. Gelderblom *et al.* (1988) used maleic anhydride coupled with reversed phase LC and UV detection for the quantitation of FB₁ and FB₂ in culture material of *F. moniliforme*. Other

derivatives used were fluorescamine (Sydenham *et al.*, 1990), naphthalene 2,3 dicarboxyaldehyde (NDA) (Bennett and Richard, 1994), maleyl derivatisation (Alberts *et al.*, 1993B) and o-phthaldialdehyde (OPA) (Shephard *et al.*, 1990; Akiyama *et al.*, 1998).

Fluorescamine was used in pre-column derivatisation of the primary amino group of fumonisins for their determination by reverse phase LC with fluorescence detection, however, the method is inconclusive, as 2 peaks are formed of acid/alcohol and lactone derivatives (Ross *et al.*, 1991). Scott and Lawrence's (1994) method, using 4-fluoro-7-nitrobenzofurazan (NBD-F), gave moderately stable derivatives and as little as 1 ng FB₁ can be detected with a linear response up to at least 50 ng injected. In this method reversed-phase LC (C18 column) was carried out with a mobile phase of methanol/ 0,05 M sodium dihydrogen phosphate, adjusted to pH 5 (1:1). The mobile phase was altered after 5 minutes by introducing acetonitrile/water v/v (8:2) at a ratio 1:1. A detection limit of 100 ng/g was obtained in the analysis of maize samples. Quantitation of fumonisins in maize using the NBD-F and NDA methods was in agreement (Scott and Lawrence, 1994). Holcomb *et al* (1993) used (9-fluorenylmethyl) chloromate (FMOC) to derivatise fumonisins with gradient elution and fluorescence HPLC and found the method to be more reliable than the above methods. Akiyama *et al* (1995) used pre-column derivatisation with 4-(N,N-dimethylaminosulphonyl) -7-fluoro-2,1,3 benzoxadiazole for fumonisins. Maragos (1995) used fluorescein 5-isothiocyanate (FITC "isomer 1") derivatisation with gradient elution and fluorescence detection. This method is unique in that the same derivatives may be used on capillary electrophoresis.

The OPA derivatives have proved most sensitive, accurate and reproducible with a

detection limit of 50 ng/g (Shephard *et al.*, 1990). Thiel *et al.*, (1993) reported an inter-laboratory comparative trial with OPA with contaminated maize, which gave relative standard deviation (RSD) values varying from 18 to 27 % amongst laboratories. The only disadvantage of the technique is that the OPA derivative is unstable after approximately 2 minutes. The OPA derivative of fumonisin B₁ was also prepared in the presence of 2-methyl-2-propanethiol and analysed on HPLC with fluorescence and electrochemical (EC) detection. The EC response of the derivative was unstable, but that with fluorescence was stable for up to 30 minutes giving a detection limit of 30 ng/ml as compared to 250 ng/ml for ECD. Plasma and urine have also been analysed for FB₁ presence using OPA derivatisation (Shephard *et al.*, 1992A) .

Evaporative light scattering detection with HPLC (HPLC-ELSD) carried out on a gradient of tri-fluoroacetic acid buffer (pH 2.7) and acetonitrile gave good separation and purification of 4 fumonisins, without derivatisation.

1.4.3 Mass spectroscopy (MS)

Fumonisin were also analysed using thermospray (TSMS), fast-atom bombardment (FABMS) and electrospray mass spectrometry (ESMS)(Korfmacher *et al.*, 1991).

Thermospray MS was not found to be suitable for the analysis of ng quantities of fumonisins, however both FABMS and ESMS provided useful data. Plattner *et al.* (1991) has analysed maize for FB₁ presence using gas chromatography with MS. More recently Plattner (1999) has achieved sensitive detection limits for fumonisin analysis, using HPLC ESMS detection, especially of the N-acetylated fumonisin that are not otherwise easily

detected. On-line capillary LC with FABMS has also been used to detect fumonisins (Xie *et al.*, 1997). High-performance liquid chromatography coupled with ESMS was also used to quantitate fumonisins (Churchwell *et al.*, 1997; Josephs, 1996; Wilkes and Sutherland, 1998).

1.4.4 Immunoassay (IA)

In order to avoid extreme costs and time requirements necessary for the above analytical techniques, alternatives for screening cereals for mycotoxins were looked at by various workers (Pestka *et al.*, 1994; Chu and Li, 1994; Usleber *et al.*, 1994). A commercial test (Fumoni Test, Vicam) uses monoclonal antibodies in an affinity column for fumonisin detection at 1 ppm level. The quantitation of FB₁ in the above may be carried out using a fluorometer. Many EIA methods have been developed to quantitate down to ppb levels (Usleber *et al.*, 1994; Schneider *et al.*, 1995; Scott *et al.*, 1997). Enzyme immunoassay compared well with HPLC results having recoveries close to 100 %. A computer assisted multianalyte system has also been developed by Abouzied and Pestaka. (1994) using the line immunoblot method. Another ELISA kit is available from Neogen Corporation called the VERATOX kit for quantitating nanogram amounts of FB₁ in commodities.

1.4.5 Capillary Electrophoresis (CE)

More recently CE has been developed as a complementary method of analysis to HPLC. This method depends upon a high voltage (20-30 kV) being applied down a fused silica capillary of 1 μ m diameter filled with a suitable buffer and cooled to avoid heating effects.

Not only ionised molecules of the correct charge pass down the capillary but also uncharged and opposite charge due to ion flow created in the buffer. Fumonisin, having ionisable groups, would seem to be highly suitable to this method, which has the advantage of a very high resolving power, although the sensitivity at the moment is not as good as fluorescence detection used with HPLC. A method has been developed using this instrumentation by Maragos (1995) which also employs a derivatizing reagent, fluorescein 5-isothiocyanate and another with ESMS as a detection method (Hines *et al.*, 1995). Capillary electrophoresis has also been combined with immunofluorescence for the detection of FB₁ (Maragos, 1997).

1.5 Pathophysiology of fumonisin intoxication

1.5.1 Effects on animals

Horses:

Horses were found to be affected by ELEM as early as 1979 (Buck *et al.*, 1979). The disease (ELEM) has also been shown by numerous researchers to be directly related to intake of *Fusarium* contaminated feed (Kellerman *et al.*, 1990; Wilkins *et al.*, 1994; Riley *et al.*, 1997) and was found to occur especially during the winter months. The literature on the ELEM can be divided into parts, i.e., the natural occurrence of the disease and experimentally induced disease with toxigenic strains of *F. moniliforme* or pure FB₁.

In earlier reported cases of ELEM (Wilson *et al.*, 1971; Kellerman *et al.*, 1990; Marasas *et al.*, 1976; Buck *et al.*, 1979; Wilson *et al.*, 1992; Domenech *et al.*, 1984) common elements are observed as follows : the animal develops inappetance after a period of eating

contaminated feed; being lethargic; and as neurotoxic effects become apparent, develops uncoordinated movement and aimless walking with blindness and violent blunderings into the front of stalls and walls. In general the animal will become difficult to handle and ill tempered. In some cases, death can occur without any nervous symptoms and in others, liver related symptoms are seen such as swelling of the lips and nose, severe icterus, with petechial haemorrhages in the mucous membranes and cyanosis.

Two main types of histopathological signs are found on autopsy, those involving the brain where oedema in the form of an accumulation of clear fluid under the meninges is seen and liquefaction of areas within the cerebral hemispheres is found, causing lesions that might range in size from microscopic to one occupying most of the lobe. In severe cases there may be a large liquified cavity within the white matter of the right cerebral hemisphere with the cerebrum posterior to the cavity enlarged and oedematous with congested blood vessels (Fig.3).

The other organ affected was the liver which often showed a mild swelling with a change in colour (yellow brown). In more severe cases gross liver lesions may be seen with fibrosis of the centrilobular area. Hepatocytes on the edge of the fibrotic area have large fatty globules in their cytoplasm.

These observations are in general supported by field outbreaks of ELEM where fumonisins were determined in the feed (Thiel *et al.*, 1991; Ross *et al.*, 1991; Wilson *et al.*, 1992) or by experiments using fumonisins in added cultured material (Kellerman *et al.*, 1988; Ross *et al.*, 1992) or administered as purified compounds (Marasas *et al.*, 1988; Laurent *et al.*,



Fig. 3 Toxic fumonisins cause liquefaction of the brain cells of animals, resulting in the fatal hole-in-the-head disease.

1989; Kellerman *et al.*, 1990). In addition to ELEM, the role of *F. moniliforme* cultures was also linked to duodenitis and proximal jejunitis in horses (Schumacher *et al.*, 1995). It was thought that this condition which is characterized by a copious reflux of gastric juice did not have a bacterial cause and might be related to FB₁ and four other mycotoxins that cause neurotoxicological symptoms. For a correct diagnosis the specific mycotoxin has to be isolated and identified from the feed.

Donkeys:

In examining the effects of maize inoculated with a toxigenic strain of *F. moniliforme* (derived from an outbreak of ELEM) on 3 horses and 3 donkeys, Kellerman *et al.* (1972) observed varying results. One horse and one donkey were unaffected, one donkey developed a transient pruritus and the remaining animals died. Observation on autopsy of the animals were similar, the gross lesions being severe cardiac haemorrhages, oedema, icterus and liver damage. No brain lesions, other than small peri-vascular haemorrhages were found. With hindsight it seem very likely that these effects were caused by a combination of *Fusarium* toxins. Other studies involving feeding donkeys with infected material were done by Badiali *et al.* (1968) and Haliburton *et al.* (1979). In all these studies the animals were found to develop ELEM in varying degrees.

Ponies:

Ponies were given feed containing a maize culture of a strain of *F. moniliforme* associated with an outbreak of ELEM. Of the five experimental ponies, one developed clinical signs of toxicity and on autopsy was found to have brain lesions consistent with ELEM. Following their observation that fumonisins can alter sphingosine metabolism Wang *et al.* (1992) gave ponies feed containing 15 to 44 mg/kg FB₁. They found, in addition to liver cytotoxicity, encephalopathy, death and elevation in free sphingosine to sphinganine blood

levels occurred. The latter effects rapidly appeared and it was suggested that such measurements could be used as early markers for exposure to fumonisin. Similar symptoms were also observed by Ross *et al.* (1992) in a feeding trial with FB₁ on 4 ponies.

Another study was done by Wilson *et al.* (1992) to determine the minimum toxic dose of FB₁ on ponies. A group of 4 ponies were fed rations with 1-22 mg/kg and a second group of 5 animals 8 mg/kg. One pony in the first group died with ELEM after 225 days feeding (last 22 days of the diet contained 22 mg/kg) the other animals having various degrees of lesion mainly associated with liver and cerebral hemispheres. The second group of ponies showed mild transient clinical signs and autopsy revealed mild brain lesions.

Pigs:

An outbreak of disease in pigs in Georgia, USA in 1989 was investigated by Harrison *et al.* (1990). On autopsy the animals had pulmonary oedema and hydrothorax with the thoracic cavities being filled with a yellow liquid. The problem was traced to maize screenings and *F. moniliforme* was isolated leading to the suspicion that a mycotoxicosis was involved. Four pigs were injected in the cranial vena cava (blood system of the brain) with various amounts of FB₁ and FB₂. The one that received the highest dose, 0.4 mg/kg body weight for four days, a total of 11.3 mg, died on the fifth day and exhibited similar lesions to the pigs involved in the field outbreak.

Another outbreak of disease in Georgia, USA was characterized by foetal mortality, and in older animals by respiratory disorders (Osweiler *et al.*, 1992). Feed samples were later taken from outbreaks of disease in Illinois and Iowa and analysed for fumonisin, which were found to be positive. Fumonisin B₁ was found to range from 20 - 330 mg/kg.

Several studies link, what has been called porcine pulmonary oedema syndrome (PPE) with outbreaks of ELEM (Ross *et al.*, 1991) and it soon became accepted that the two diseases had a common cause, i.e., fumonisin.

Experimental feed studies of pigs were carried out using either naturally contaminated feed with fumonisins at known levels (Casteel *et al.*, 1993; Haschek *et al.*, 1992; Colvin *et al.*, 1992,1993) or by injection with quantities of purified fumonisin (Harrison *et al.*, 1990). In general animals fed high levels of FB₁, died with pulmonary oedema and those surviving on lower levels, had evidence of subacute hepatotoxicosis. From the limited evidence, animals receiving pure toxin were more likely to develop pulmonary oedema, whereas those on naturally contaminated feed had both lesions. In one study pigs that were fed with 100-190 mg/kg FB₁ developed nodular hyperplasia of the liver and tissue damage to the oesophageal mucosa. Synergistic effects are known between other mycotoxins, including FB₁ with fusaric acid (Bacon *et al.*, 1995).

Feeding FB₁ to lactating sows did not affect suckling pigs and there was not evidence of the toxin present in the milk (Becker *et al.*, 1995). This agrees with other studies on cow's milk (Scott *et al.*, 1994).

As with other animal studies the uptake of ¹⁴C labelled FB₁ administered intra-gastrally to pigs was poor (3-6%). When fumonisin was given intraperitoneally (ip), elimination was rapid and 80 % of the dose was recovered within 3 days in the excreta with the remainder being associated with the liver and kidney (Prelusky *et al.*, 1994). Riley *et al.* (1993) found alterations in sphinganine to sphingosine ratios in pigs fed diets containing FB₁ and FB₂

and also suggested this as an early biomarker for exposure to the toxin.

Rats:

Prior to the discovery of the fumonisins, several trials had been done where rats were dosed with feed infected with *F. moniliforme* related to outbreaks of ELEM (Voss *et al.*, 1998) or to OC (Jaskiewicz *et al.*, 1987; Gelderblom *et al.*, 1988). In general these studies indicated the presence of an hepatocarcinogen in these cultures with the development of hepatic nodules, adenofibrosis, hepatocellular carcinoma - ductular carcinoma and cholangiocarcinoma.

Several studies on the rat were conducted by the workers at PROMEC (Gelderblom *et al.*, 1992; Shephard *et al.*, 1994) exploring the absorption and excretion of fumonisins and its effects on the animals.

Radio-labelled FB₁ studies using ip administration of ¹⁴C - FB₁ was carried out on tissues from the kidney of the rat. Of the material given orally 101 % of fumonisin was found in the faeces. The extra 1% may have been previously present in the system of the rat. A further study (Shephard *et al.*, 1994) clarified how FB₁ ended up in the faeces of animals dosed intra-peritoneally (ip). Sixty seven percent of the dose in this latter study was found in the bile of the rat.

Evidently only a small portion of the doses (<1%) are absorbed from the gastrointestinal tract (GIT) which is understandable considering their high polarity and presumable lack of membrane transport systems. This may explain why relatively high levels of contamination of feed are required >5 mg/kg to produce symptoms in animals but it also indicates that

the fumonisins must be highly active once internalised.

Other work reported by the PROMEC group shows that the fumonisins are hepatotoxins and carcinogens in the rat (Gelderblom *et al.*, 1997). Culture material from *F. moniliforme* fed to rats produced micro and macronodular cirrhosis in animals that died, cholangiofibrosis and primary adenofibrosis (Gelderblom *et al.*, 1991; Wilson *et al.*, 1992). Tubular nephrosis was found in the renal cortex of animals fed material infected with *F. moniliforme* associated with outbreaks of ELEM (Voss *et al.*, 1998). Inhibition of protein synthesis in hepatocytes was also found (Norred *et al.*, 1990). Later work, where purified FB₁ was fed to rats, showed that sphingolipid metabolism in the kidney is more susceptible to the toxin than in liver (Riley *et al.*, 1994). Various markers of nephrotoxicity were measured in rats dosed with FB₁ (Suzuki *et al.*, 1995). The use of ¹⁴C- labelled FB₁ as a single dose to rats, killed at time intervals gave recoveries of the label in faeces and urine of over 80 % (Norred *et al.*, 1993). The balance, however, remained in the blood, liver and kidney for the duration of the experiment, i.e., up to 96 hours, which does not quite agree with the PROMEC results, in that larger quantities remained bound in the animal.

Lebepe-Mazur *et al.* (1995) showed that FB₁ affected the foetus in pregnant rats, causing low litter weights and impaired foetal bone development, as compared to untreated controls, and found that placental glutathione S-transferase was a more useful marker in this case than glutamyl transferase in detecting hepatic cancer foci (Ferguson *et al.*, 1997).

Other Rodents :

Pregnant mice fed culture material containing known amounts of fumonisin were shown to

have lowered body weights, increased morbidity and mortality in a a dosed response way (Gross *et al.*, 1994). Other observations were, liver damage and ascites and a reduction in the number of live offspring.

Similar results were found in another investigation which indicated that FB₁ fed at < 81 ppm to female mice caused hepatotoxicity and doses at 27 ppm or less had no effect, which is in contrast to the rat where nephrosis was observed at 9 ppm (Voss *et al.*, 1998).

Fumonisin B₁ fed to Syrian hamsters at a rate of 18 ppm also resulted in increased foetal deaths but without evidence of maternal intoxication (Floss *et al.*, 1994).

Poultry:

Maize based feeds for chicken have been found to be often contaminated with *F. moniliforme* (Bragulat *et al.*, 1995). Day old broiler chicks were fed doses of FB₁ ranging from 0 to 400 mg/kg for 21 days and 300 mg/kg for 2 weeks (Brown *et al.*, 1996). Body weight gain was gradually reduced, hepatic necrosis, biliary hyperplasia and thymic cortical atrophy were noted along with diarrhoea and rickets. A further investigation (Weibking *et al.*, 1993) revealed increased sphinganine and sphinganine:sphingosine ratios in young poultry treated with culture material containing FB₁. Turkeys also showed pathology due to fumonisin and moniliformin (Bermudez *et al.*, 1997; Kubena *et al.*, 1997B; Ledoux and Rottinghaus., 1996).

Abnormal erythrocyte formation and lymphocyte cytotoxic effects were also found in poultry (Javed *et al.*, 1993). Chicken embryos exposed to FB₁ showed a mortality of a 100 % when dosed at 100 μ M. Pathological changes were found in liver, kidney, heart, lungs, musculoskeletal system, intestines, testes and brain (Javed *et al.*, 1993). Espada *et al.*

(1994) showed that 10 mg/kg feed for 6 days was toxic to young chicks. Laying hens (Vudathala *et al.*, 1994) also showed poor oral uptake and rapid excretion of the ip dose, although no FB₁ residues were found in the eggs.

Chatterjee *et al.* (1994) examined the effects of FB₁ on chicken peritoneal macrophages and found them to exhibit breakdown of the nucleus with increasing numbers in a dose response manner (6-18 µg/ml). This suggests impaired disease immunity in chickens (Marijanovic *et al.*, 1991). Vitamin A was depleted in the serum of broiler chicks (Hall *et al.*, 1995). Combined effects of mycotoxins were investigated in broiler chicks by Kubena *et al.*

(1997A). Ducklings had slightly swollen and reddened livers with low body fat. Turkey poults showed variations in body and organ weight increase. Generalised hepatocellular hyperplasia was found in all the treated poults. Biliary hyperplasia and turkey cerebral encephalomalacia were also noted in turkey. The combined feeding of aflatoxin and fumonisin to turkey poults showed a variation in body and organ weights (Weibking *et al.*, 1994 ; Kubena *et al.*, 1997B).

Primate Studies:

Prior to isolation of the fumonisins, as part of a study on the effect of toxic extracts of *F. moniliforme* on animals, baboons were found to develop hepatic cirrhosis and intraventricular thrombosis (Kriek *et al.*, 1981). In another investigation 10 young vervet monkeys were fed *F. moniliforme* culture material (Jaskiewicz *et al.*, 1987). This was found to cause toxic hepatitis of varying degrees related to the amount fed with the release of liver enzymes into the serum paralleling the liver damage. In another trial four male and seven female vervet monkeys were fed cultured material containing FB₁, FB₂ and FB₃

(Fincham *et al.*, 1992). Days of feeding ranging from 40 to 573 on a “high” dose regime (total fumonisin ranging from 784-3257 $\mu\text{g}/\text{vervet}/\text{day}$). The unexpected result was that the appearance of hyper-cholesterolaemia, all treated animals having statistically significant increased serum cholesterol over that of controls and with raised plasma fibrinogen and activity of factor V11 which would enhance atherogenesis. In addition chronic hepatotoxicity was observed, which is in keeping with the findings in other animal species.

Further work on primates (Shephard *et al.*, 1994) was aimed at investigating their absorption and excretion of fumonisin as previously studied in rats (Shephard *et al.*, 1992B). In this case, however, extraction from faeces was effected using EDTA, which presumably allowed the release of the fumonisins from metal chelaters. In one experiment two vervet monkeys were given radio-labelled FB_1 at a rate of 8 mg/kg body weight. The bulk of the radio-label FB_1 was found in the faeces, both unchanged and as partially hydrolysed monoesterase derivatives.

In a later more detailed investigation using four vervet monkeys (Shephard *et al.*, 1994B) radio-labelled toxin was administered by gavage or ip injection. From two animals treated by ip injection, 47 % of the dose was recovered in urine and faeces over 5 days, as FB_1 or its partially hydrolysed derivatives whereas 61 % was recovered from those dosed by gavage. A further 15 % was accounted for in the latter animals, mainly as intestinal contents with small amounts in skeletal muscle, liver, brain, kidney, heart, erythrocytes and bile. This result is intriguing as a quarter of the fed material could not be accounted for which is in contrast with the experiment with rats.

Other Animals:

One case of ELEM symptoms in white tailed deer has been described in the USA (Howarth *et al.*, 1989) which seems to have been caused by the animal finding a source of infected maize. Calves given feed containing FB₁ up to 148 mg/kg were unaffected in terms of feed intake or weight gain, although certain blood enzymes were elevated along with cholesterol (Osweiler *et al.*, 1993).

Lambs dosed with fumonisin showed evidence of liver and kidney damage. Those that received 44.5 mg/kg fumonisin died (Edrington *et al.*, 1995). Liver and kidney damage were also observed in mink given chronic doses of fumonisins (Restum *et al.*, 1995).

1.5.2 Humans

Fumonisin and oesophageal cancer (OC):

The discovery of the fumonisins derived directly from the investigation by the PROMEC group of human oesophageal cancer (OC) in the Transkei in S.Africa. Oesophageal cancer occurs in geographical pockets around the world e.g., China (Yang, 1980) and was first reported in the Transkei in 1957 (Burrell, 1957) an observation that was amply confirmed (Jaskiewicz *et al.*, 1987; Rose, 1973). As in most rural communities in Southern Africa the main staple diet is maize. It was well established that maize grown in this region was susceptible to infection by several fungi, in particular *Fusarium* spp. (Marasas *et al.*, 1979; 1988; Segal *et al.*, 1988) and of these *F. moniliforme* and *F. subglutinans* were the most prevalent with *Diplodia maydis* being third. Because of the high incidence of these fungi together with their mycotoxins they were investigated in outbreaks of OC. Burrell (1957) found OC in the Bantu in South Africa which may been caused by dietary exposure to

fumonisin.

A significant difference in the levels of fumonisin in maize and maize used for making home brewed beer (Rheeder *et al.*, 1992; Marasas *et al.*, 1993) between high and low OC areas was found. A similar distribution was found in China (Chu and Li, 1994; Yoshizawa *et al.*, 1994) where the incidence of fumonisin in high risk areas was thrice that of low risk.

1.5.3 Tissues and cell culture

The fumonisins are cytotoxic (Norred *et al.*, 1996) and the effects of FB₁ and FB₂ were tested on several mammalian cell lines including rat hepatoma and dog kidney epithelial cells. Fumonisin B₁ was also found to inhibit protein synthesis (Norred *et al.*, 1990) and inhibit the secretion of ceramide into very low density lipoprotein (Merrill *et al.*, 1995). Chick embryos and brine shrimp bioassay showed toxicity from fumonisin B₁ (Hlywka and Bullerman, 1997).

Turkey lymphocytes were used in an MTT-based cytotoxicity assay by Dombrink-Kurtzman *et al.* (1994) and the 50 % inhibitory dose for FB₁ or FB₂ was 0.4-0.5 µg/ml medium (Smith, 1996). Cells exposed to the toxins exhibited vasculization and were unable to proliferate. Chicken chondrocytes in culture were exposed to FB₁ which was inhibited by levels as low as 25 µg. Baby hamster kidney cells also showed pathology (Abeywickrama and Bean, 1992).

The yeasts, *Saccharomyces cerevisiae* (Wu *et al.*, 1995) and *Pichia* spp developed abnormalities in their sphingolipid metabolism showing that lower organisms are equally affected by the toxin. The bioluminescent genotoxicity test using *Vibrio fischeri* revealed that FB₁ was directly mutagenic. This was in contrast to the Ames test, as FB₁ exhibited cytotoxicity but no mutagenicity activity of *F. moniliforme* isolates.

In green monkey kidney cells treated with FB₁ the toxin was found to repress expression of protein kinase C, whereas it stimulated the promoter of a cyclic AMP receptor (Huang *et al.*, 1995). LaBorde *et al.* (1997) showed no embryo toxicity to FB₁ in New Zealand white rabbits.

1.5.4 Mode of Action

Wang *et al.* (1991) showed that FB₁ disrupted sphingolipid biosynthesis in rat hepatocytes. A further investigation using rat hepatocytes and pig kidney epithelial cells (Norred *et al.*, 1997) confirmed that the fumonisins were potent inhibitors of sphingolipid biosynthesis in both types of cell, killing the renal cells after 3 days at a level of 70 μ M of FB₁. This effect was further studied in mouse cerebellar neurons (Merrill *et al.*, 1993, 1996; Rother *et al.*, 1992) cells, where it was shown that FB₁ specifically inhibited the conversion of sphinganine to dihydroceramides. The inhibitory effect on neuron cultures of FB₁ was demonstrated where treated hippocampal neuron axonal growth was completely suppressed as was short term axonal branching (Schwartz *et al.*, 1995).

It was pointed out by Wang *et al.* (1991), that the structure of the backbone of the

fumonisin molecule, was similar to the important phospholipid, sphingosine (Fig.1). Hence FB_1 may exert its action by interfering with its metabolism and processes mediated by this type of molecule, such as the inhibition of protein kinase C, and via ceramides, regulation of cell growth, differentiation and apoptosis (Huang *et al.*, 1995). Ramasamy *et al.* (1995) have shown that FB_1 increases the rate of albumin transfer across endothelial cell monolayers derived from pulmonary artery, in addition to elevation of sphinganine levels, the latter possibly explaining the loss of endothelial barrier function.

Morgan *et al.* (1997) investigated the effect of FB_1 on Swiss 3TS fibroblasts, and found an accumulation of sphinganine, which was greatly promoted by the presence of insulin. This led to an increase in DNA synthesis. This mitogenic nature of fumonisin also gives a lead to the mechanism of tumour promotion by FB_1 by the stimulation cell proliferation. In addition the possible influence of dietary sphingolipid and fumonisin on the role of fat in disease has been reviewed by Merrill *et al.* (1995,1996). Morgan *et al.* (1997) found an increase in the free sphingosine to sphinganine ratio in urine and liver. A HPLC method to quantitate sphingosine has also been developed (Merrill *et al.*, 1988; Solfrizzo *et al.*, 1997).

1.5.5 Pre-eclampsia and Fumonisin

Both pre-eclampsia in humans and FB_1 intoxication in animals produce a large number of pathophysiological effects involving most of the major organs of the body such as liver, kidney and brain. Bermudez *et al.* (1997) and Bondy *et al.* (1995) found that intake of FB_1 caused decreased foetal body weight gains in pregnant rats with diffuse hepatocellular

hyperplasia and nephrotoxicity . This was confirmed by Suzuki *et al.* (1995) . Table 2 shows some of the common effects caused during pre-eclampsia and fumonisin toxicoses. Often perioperative seizures have to be managed in pre-eclampsia (Cheng and Kwan, 1997). Blood plasma in eclampsia shows a high free radical trapping ability (Jendryczko and Tomala, 1995). Magnesium sulphate is often used in seizure prevention in pre-eclampsia (Anthony *et al.*, 1996; Handwerker *et al.*, 1995). Magnesium also combines well with FB₁ which is a good metal chelator. Magnesium may thus be instrumental in removing free FB₁ in pre-eclamptic women thus reducing the severity of the disease. The role of nutritional factors, including agricultural products, in pre-eclampsia and eclampsia was discussed by Vasiljevic *et al.* (1996). The role of obesity and the risk of toxemia in pregnancy was found to contribute to pregnancy disorders (Fields *et al.*, 1994).

Insulin inhibits the symptoms of pre-eclampsia (Maharaj and Moodley, 1994) and fumonosis by increasing sphinganine levels in fibroblasts (Morgan *et al.*, 1997). Another study showed that FB₁ is detoxified by fructose (Lu *et al.*, 1997) indicating that the presence of carbohydrates in animals or humans may decrease fumonosis and pre-eclampsia.

Table 2. Pathophysiological effects common to pre-eclampsia/eclampsia (PE) and animal fumonosis (F).

ORGAN / SYSTEM	PATHOPHYSIOLOGICAL EFFECTS OF <i>PE</i> AND <i>F</i>	REFERENCES & CORRESPONDING EFFECTS (Column 2)
Immune system Blood system	1. Abnormal ratio of prostoglandin to thromboxane 2. Increased platelet level 3. Vasoconstriction, increased blood pressure 4. Blood coagulation 5. Increased epinephrine/norepinephrine 6. Increased amino acids and ammonia 7. Increased sphingolipid conc. 8. Increased plasma ascorbic acid 9. Immuno-compromised	Moodley, 1991 - PE/1,3 Martinova and Merrill, 1985 - F/2 Goel <i>et al.</i> , 1996 - F/7 Halim <i>et al.</i> , 1995 - PE/4 Khatun <i>et al.</i> , 1997 - PE/5 Li <i>et al.</i> , 1996 - PE/6 Ozan <i>et al.</i> , 1997 - PE/8 Tryphonas <i>et al.</i> , 1997 - F/9
Placenta/foetus	1. Immunological defect 2. Low birth weight 3. Foetal distress/death	Moodley, 1991 - PE/1,3 Ferguson <i>et al.</i> , 1997 - F/2 Lebepe-Mazur <i>et al.</i> , 1995 - F/3 McCowan <i>et al.</i> , 1996 - PE/3 Voss <i>et al.</i> , 1998 - F/2 Floss <i>et al.</i> , 1994 - F/2,3

Kidney	<ol style="list-style-type: none"> 1. Proteinuria 2. Renal failure 3. Histopathology 	<p>Moodley, 1996 - PE/1,2</p> <p>Bondy <i>et al.</i>, 1995 - F/2</p> <p>Beek <i>et al.</i>, 1998 - PE/1,2</p> <p>Edrington <i>et al.</i>, 1995 - F/2</p> <p>Gurel <i>et al.</i>, 1998 - PE/1,2</p> <p>Naicker <i>et al.</i>, 1997 - PE/3</p> <p>Randeree <i>et al.</i>, 1995- PE/2</p> <p>Riley <i>et al.</i>, 1994 - F/2</p> <p>Shaarawy <i>et al.</i>, 1997 - PE/3</p> <p>Bucci <i>et al.</i>, 1998 - F/2</p>
Liver	<ol style="list-style-type: none"> 1. Hepatocellular damage 2. Liver enzyme elevation 3. Acute fatty liver 4. Liver cancer 	<p>Moodley, 1991 - PE/1,2,3</p> <p>Cawood <i>et al.</i>, 1994 - F/1</p> <p>Gelderblom <i>et al.</i>, 1995;</p> <p>1996A,B- F/1</p> <p>Marasas <i>et al.</i>, 1984 - F/1,4</p> <p>Knasmuller <i>et al.</i>, 1997 - F/1</p> <p>Norred <i>et al.</i>, 1990,1997 - F/1</p> <p>Sharma <i>et al.</i>, 1997 - F/1</p> <p>Edrington <i>et al.</i>, 1995 - F/1</p> <p>Voss <i>et al.</i>, 1998 - F/1</p> <p>Gross <i>et al.</i>, 1994 - F/1</p> <p>Ueno <i>et al.</i>, 1997 - F/4</p>

Hematological	1. Hemolytic anaemia 2. Thrombocytopenia 3. Erythrocyte fragility	Moodley., 1991 - PE/1 Srivastava <i>et al.</i> , 1995 - PE/2 Ozan <i>et al.</i> , 1997 - PE/3
Heart	1. Heart arrhythmias	Moodley ,1991 - PE/1 Casteel <i>et al.</i> , 1994 - F/1
Lungs	1. Pulmonary oedema	Moodley, 1991 - PE/1 Casteel <i>et al.</i> , 1994 - F/1 Colvin <i>et al.</i> , 1993 - F/1 Guzman <i>et al.</i> , 1997A;B - F/1 Rotter <i>et al.</i> , 1996 - F1
Brain	1. Seizures 2. Cerebral oedema 3. Encephalopathy 4. Haemorrhage 5. Altered sphingolipid	Moodley, 1991 - PE/1,2,4 Badiali <i>et al.</i> , 1968 - F/2 Caramelli <i>et al.</i> , 1993 - F/2 Cheng <i>et al.</i> , 1997 - PE/1 Beek <i>et al.</i> , 1998 - PE/1,2 Howerth <i>et al.</i> , 1989 - F/2 Ito <i>et al.</i> , 1995 - PE/2 Witlin <i>et al.</i> , 1997 - PE/2 Manfredi <i>et al.</i> , 1997 - PE/3 Bucci <i>et al.</i> , 1996 - F/4 Plumlee and Galey, 1994 - F/2 Kwon <i>et al.</i> , 1997 - F/5

CHAPTER 2

2.0 PRODUCTION FUMONISIN B₁

2.1 Introduction

Fungi of the genus *Fusarium* are found in plant debris and crop plants worldwide (Marasas *et al.*, 1993). Several species from this genus are economically important because, in addition to their ability to infect important crops, such as maize, wheat and other small grains in the field, they produce mycotoxins in the crops in the field and in storage. The presence of high levels of mycotoxins in grains poses a significant economic threat because animals that consume contaminated grains may perform poorly or even become sick and die. The threat of mycotoxins entering the human food supply through contaminated grain products and exposed animals is also a concern for regulatory officials.

Fumonisin is produced by the fungus *F. moniliforme* and some closely related species in section *Liseola*. Fumonisin B₁ is generally the most abundant member of the family of fumonisins. This study sought to investigate the growth of the fungus, *F. moniliforme*, and its potential to produce FB₁ in solid and liquid culture. Toxin production was analysed qualitatively using thin-layer chromatography.

2.2 Materials and Methods

2.2.1 Preparation of inoculum

Fusarium moniliforme PPR1 1059 (Mercen culture collection) was stored at -20° C. The organism was sub-cultured on Sabouraud Dextrose Agar (SDA) McCartney slants and on petri dishes and incubated for 14 days at 28 °C until complete sporulation occurred. The slants were stored long-term at 4 °C. Spores on the petri dishes were harvested by washing the surface of the agar plates with 1ml sterile distilled water to prepare a conidial suspension. The suspension was quantitated using a 0.5 Mc Farland standard (0.5% Barium solution) comparing turbidity and stored at 4 °C until use.

2.2.2 Reagents and Solvents

All the salts and solvents were of analytical grade and were purchased from Merck NT.

2.2.3 Broth culture and extraction of fumonisin B₁

The broth used for the production of FB₁ consisted of glucose, 90g; KH₂PO₄, 2g; (NH₄)₂SO₄, 3,5g; Mg SO₄, 0.3g; CaCl₂, 0.4g; MnSO₄, 0.016g in 1 litre deionised water and corresponded to Alberts's *et al.*(1994) broth culture A. Broth F, a non-producer of FB₁ (Alberts *et al.*,1994) was used as a control. Three 1 litre volumes of broth A media were dispensed in Erlenmeyer flasks (2 litre), sterilized by autoclaving at 121 °C for 15 minutes, inoculated with spore suspension (1 ml) and incubated on a shaking incubator at

26 °C for 28 days. The broths were sampled and analysed by TLC every 2 days to check for FB₁ production. The cultures were harvested after 28 days incubation.

The broths were centrifuged at 12 000 RPM for 15 minutes in a Beckman floor centrifuge and the supernatant was filtered on a Buchner. One hundred grams of Amberlite IRA beads in 500 ml methanol was poured into a 100 x 2.5 cm long glass column giving a packed bed length of 60 cm (Fig.4). A tap at the bottom of the glass column was used to regulate the flow rate of the solvents. The column was pre-conditioned with 350 ml methanol and 350 ml methanol/ water v/v (3:1). The filtrate was run onto the column thereafter at 2 ml/min. The column was washed with 350 ml methanol/ water and 350 ml methanol. Fumonisin B₁ was eluted with 700 ml of 1% acetic acid in methanol. Thirty fractions (10 ml) were collected in McCartney bottles, and were later analysed by TLC (2.2.5).

2.2.4 Maize patty culture of fumonisin B₁

A mix of maize meal and deionised water (1.2 ml/g) was prepared and 30 g was added to each of 30 glass petri dishes. These were immediately autoclaved for 1 hour at 15 psi, and re-autoclaved on the following day. Cooled plates were then inoculated with a 1 ml spore suspension of *F. moniliforme* PPR1 1059. The inoculum was kept constant for all patties. The plates were then incubated in the dark at 26 °C (incubator) for 6 weeks.

After incubation the contaminated patties were discarded and 14 patty cultures were labelled A to N. These were oven dried at 45 °C for 48 hours. Liquid extraction was carried out on 5 g samples of each plate, by blending with 100 ml of methanol/ water v/v




Fig. 4 Amberlite IRA beads used to clean-up *F. moniliforme* broth culture.

(3:1) for 3 minutes at 60% of the full speed. The material was added to a 250 ml centrifuge bottle and spun at 500 g for 10 minutes at 4 °C. The supernatant was filtered through fluted No.4 paper and the filtrate was adjusted to pH 5.8.

Strong anion exchange columns (SAX)(Bond-elut, Varian) were used to purify the FB₁ from the patty culture extract. The columns were attached to a Vac-elut system (Fig.5) connected to vacuum and a pressure gauge. The columns were pre-conditioned with 5 ml methanol (Analar grade, Merck) and 5 ml methanol/ water v/v (3:1) at a flow rate of 1 ml/min. The filtered extract (10 ml) was then applied. The column was washed with 5 ml methanol/ water followed by 3 ml methanol. The sample was eluted with 10 ml 1 % acetic acid in methanol at a flow rate of 1 ml/min. The eluent was collected in a sterile Bijou bottle and dried under nitrogen gas until required for TLC and HPLC analysis.

2.2.5 Thin-layer chromatography (TLC)

2.2.5.1 Apparatus

TLC plates - Silica gel 60 plates (20 x 20 cm, Merck NT).

TLC developing tank - glass tank (20 x 20 cm).

TLC spray bottles - plastic bottle with fine spray nozzle.

Micro-capillary tubes - graduated 10 μ l.

2.2.5.2 Solvents

Butanol, acetic acid, acetonitrile and methanol were required. These were of analytical grade (Merck NT).




Fig. 5 Using the Bond Elut / Vac Elut™ system.

The components of the BOND ELUT / VAC ELUT system are pictured above. A 10-place molded cover (1) with a foam polyethylene gasket precisely fits the top of the vacuum basin (2). BOND ELUT columns are inserted into luer fittings (3) which are an integral part of the cover. Unused spaces are capped with plugs (4) supplied with the system. Vacuum is applied through a 1/8" NPT hose fitting (5). Sample eluants are collected in test tubes (6) which are held under the columns in several types of stainless steel removable racks (7).

2.2.5.3 Mobile phase

100 ml solution of butanol/ methanol/ acetic acid (BMA) v/v/v (6 :1.5 :2.5) was prepared and allowed to equilibrate in TLC tank.

2.2.5.5 Fumonisin B₁ standards

One milligram of FB₁ (Sigma) was dissolved in acetonitrile/ water v/v (1:1) to make a stock solution of 50 $\mu\text{g/ml}$.

2.2.5.6 Spray reagent

The reagent was prepared by mixing 85 ml methanol with 5 ml concentrated sulphuric acid and allowed to cool. Glacial acetic acid (10 ml) was added thereafter and finally 0.5 ml p-anisaldehyde (Sigma) was added. The reagent was added to an amber bottle and kept in the dark until use. The reagent was used for one week and discarded thereafter.

2.2.5.7 TLC analyses of broth and patty extracts

The 1 ml of broth sampled every 2 days, and the 30 fractions of broth eluents collected after Amberlite IRA extraction were spotted on the TLC plate in the following way. Ten μl samples of broth extract were spotted approximately 1 ml apart along the pre-concentration zone of a TLC plate and labelled appropriately. The spots were dried and the plate was placed in the TLC tank and left to develop in the mobile phase. Upon developing, the solvent front was drawn and the plate was left to air dry. Patty culture extracts A to N, were spotted as above alongside standards.

2.2.5.8 Derivatization and visualization

The dried plate was sprayed with the p-anisaldehyde spray reagent using the spray bottle to ensure an even covering of the plate. The plate was then heated in an oven at 120 °C for 5 minutes. Visual intensity of the broth spots were compared to the purple spots of the standard, FB₁. The Rf values of the broth spots were calculated using the following equation:

$$\text{Rf of FB}_1 = \frac{\text{Distance travelled by FB}_1 \text{ concentrates}}{\text{Distance of solvent front}}$$

2.3 Results

2.3.1 Broth

The triplicate A broths turned dark pink-peach 17 days after inoculation with *F. moniliforme* (Fig.6) as compared to the F broth, which produced only white mycelium. Thin-layer chromatography analysis indicated the production of FB₁ from 17 days after inoculation and at 28 days, showed maximum production of FB₁. When FB₁ was extracted from broth using the amberlite column, only the first 12 of the 30 fractions eluted FB₁ positive (Fig.7). The Rf value of FB₁ was found to be 0.92. The 12 positive fractions were pooled and kept for analysis on HPLC.

2.3.2 Maize patty culture

The maize patty cultures of *F. moniliforme* grew well over a 6 week period. They turned




Fig. 6 Broth cultures of *Fusarium moniliforme* PPR1 1059 after 17 days (Broth A : fumonisin production; Broth F : no fumonisin).




Fig. 7 TLC analysis of broth culture fractions eluted from
amberlite column after 28 days.
[Solvent system: BMA (6:1.5: 2.5), using Silica gel
60 plates]

from white to pink to purple (Fig. 8), a similar colour produced on SDA medium after 10 days (Fig. 9) but with a more even and dense growth. At the end of the incubation period the colour turned black and on drying gave a burnt appearance. This, however, did not affect the isolation of FB₁, and examination of extracts by TLC showed the presence of FB₁ in all 14 patty cultures (Fig. 10).

Quantitative analysis of the extract was carried out later using fluorescence HPLC and is reported in chapter 3 (section 3.3).



Fig.8 Petty culture of *F. moniliforme* PPR1 1059 at 26°C for 14 days




Fig. 9 *F. moniliforme* PPR1 1059 on Sabourand agar at 26°C for 1 week




Fig.10 TLC analysis of maize patty cultures (A-N) after clean-up with Bond- Elut cartridges, with Rf values of FB₁ ranging from 0.5 to 0.53. [Solvent system: chloroform / methanol / acetic acid (6 :1.5 : 2.5), using Silica gel 60 plates (Ackerman, 1991)]

2.4 Discussion

Fumonisin B₁ production

Broth A was found to be a good producer of fumonisins in keeping with the finding of Alberts *et al.* (1994). As in Jackson and Bennett's (1990) experiments, the production of FB₁ steadily rose from 17 to 28 days. Figure 7 shows a display of distinct purple spots (FB₁) away from the broth matrix spots. The purple spots were confirmed as being FB₁ due to a similar pattern being produced by a FB₁ spiked broth culture.

The maize patty cultures of *F. moniliforme* gave a very distinct purple hyphal growth. This was much more distinct as that described by other authors. The drying treatment of the culture at 45° C for 48 hours did not affect the presence of fumonisins. This indicates thermostability of FB₁.

The Bond-elut SAX cartridge (500 mg sorbent mass) is a convenient method of extraction because of its speed and ease of use as compared to preparing and using an amberlite IRA beads for the extraction of FB₁. However it may only be used to purify up to 10 ml extracts (ie. small scale). Larger scale extraction of FB₁, for example, one litre broth samples, require the manual preparation of larger columns. The 100 g Amberlite IRA bead column used in this experiment was successful in extracting the FB₁ from the broth extract. Fraction collection was time-consuming however. This may be overcome by the use of an automatic fraction collector.

The difficulty in selecting a single extracting and clean up method for fumonisins has been demonstrated above. Perhaps the development of a mycotoxin/matrix certified reference materials (CRM's) needs to be done as suggested by the European Commission in 1995. The accuracy precision and traceability of the extraction step in analytical procedures in particular to study the presence and/or effects of bound residues of mycotoxins needs to be set up for biological and biomedical matrices (Wilkes and Sutherland, 1998).

The TLC method used in the experiment was successful in indicating the presence or absence of FB_1 , provided the plates were sprayed uniformly. However, differing R_f were obtained for FB_1 depending on the substrate from which FB_1 was being extracted and the clean-up method used. Broth and patty culture matrices differ greatly and thus may have contributed to the differing R_f values of fumonisins obtained in Fig. 7 and Fig. 10.

The diffused bands noted in Fig 10 may be due to incomplete clean up of those particular extract.

A comparison of yield of FB_1 produced in broth and patty cultures is done in chapter 3 (section 3.4).

CHAPTER 3

3.0 QUANTITATION OF FUMONISIN B₁

3.1 Introduction

In order to detect and quantitate low levels of FB₁ in agricultural commodities, feeds and other biological material highly sensitive analytical techniques are required. Fumonisin are not amenable to high temperature GC analysis without derivatisation. The mycotoxin class also lacks a strong UV chromophore and so cannot be directly determined by HPLC-UV. They are formed or sequestered in complex matrices (food, tissue, physiological fluids), so that analytical sensitivity is required to differentiate them from environmental co-extractants, yet their molecules do not contain distinctive moieties useful for selective detection. The fumonisins contain four carboxyl moieties which necessitate the use of a strong acid buffer, such as trifluoroacetic acid (TFA), for good reversed-phase HPLC peak shape. However, TFA degrades fumonisins when the sample is concentrated. The first derivatisation methods for HPLC of fumonisins used maleic anhydride with UV detection or fluorescamine with fluorescence detection (Sydenham *et al.*, 1990). Maleic anhydride produced a 10 µg/g detection limit which is not sensitive enough for incurred residues. Fluorescamine produced two separate peaks for FB₁ and was also not suitable for quantitation. Eventually reaction with o-phthalaldehyde (OPA) was adopted as a more sensitive approach. This method has a 50 ng/g detection limit (Shepherd *et al.*, 1990). However, the OPA derivatives of the fumonisins are unstable. To obtain quantitatively rapid results samples must be injected onto the HPLC column at no later than 4 minutes

after the addition of the reagent. This method has been adopted as an Association of Official Analytical Chemists International (AOAC) approved method for the determination of FB₁, FB₂ and FB₃ (Sydenham *et al.*, 1997). Quantitative capillary electrophoresis (CE) results agreed closely with parallel HPLC results using pre-column 5-fluoro-isothiocyanate (FITC) derivatisation (Maragos, 1995).

The OPA method was adapted for the present study, to realise an accurate and sensitive quantitation of FB₁ in culture material (Thiel *et al.*, 1993).

3.2 Method and Materials

3.2.1 High-performance liquid chromatography (HPLC) methodology (Bettina, 1993)

The HPLC became available for the analysis of foodstuffs nearly twenty years ago. The first published HPLC application for mycotoxin research dates from 1973. Since then, the trend has been towards increased use of HPLC for the ultimate separation, detection, and quantification of the mycotoxins in foods, after sufficient clean-up to remove interferences that could give rise to false positives. A typical HPLC system is shown in Fig. 11.

The important advantages of HPLC were its ability to handle thermally labile, poorly volatile, non-volatile, polar, and ionic compounds. The high resolving power between chemically similar compounds, the speed, increased sensitivity, accuracy and precision of




Fig. 11 A representation of the components of an HPLC system.

the method, and the variety of detection systems now available make modern HPLC a more suitable technique than other liquid chromatographic techniques. In addition, HPLC is a quantitative technique and is suited for on-line clean-up of crude sample extracts, and finally, it can be automated quite easily. However HPLC has limitations as well. The cost of modern HPLC equipment is quite high, and wide experience is necessary for obtaining the best possible benefit from the HPLC system.

Instrumentation and practice

In modern mycotoxin analyses, it will be profitable to use one of the three primary HPLC methods: reversed-phase (RP), ion-pair (IP), or normal-phase (NP) chromatography. RP-HPLC is nowadays the most commonly used method, and it is a potential technique for multimycotoxin analysis under gradient elution conditions.

Instrumentation

Modern liquid chromatographs, which vary widely in sophistication, can be assembled from modular units designed to work independently of each other, or purchased as a single, integrated unit. Each system has its own advantages and drawbacks.

Solvent reservoir

The solvent reservoir must hold a volume of solvent adequate for repeated analyses and it must be inert with respect to the solvents used, varying from aqueous buffers to hydrocarbons, depending on the mode of chromatography. Air bubbles are the major cause of problems with LC pumps. Problems with dissolved air are usually encountered with protic solvents such as water and alcohols. The best way to avoid bubbles is to thoroughly degas the solvents by heating, application of vacuum or ultrasound, or by sparging with helium. The latter is the most effective and convenient degassing method. After initial

(a few minutes) vigorous bubbling of helium through the solvents the helium flow is reduced to a trickle during the use of the LC system.

Pumping systems

The pump is one of the most important components in HPLC equipment, because its performance directly affects the reproducibility of retention times, quantitative analysis, and detector sensitivity. Nowadays reciprocating piston pumps provide the basis for most pumping systems. The pump must produce a wide range of flow rates for solvent delivery. Although most HPLC pumps operate at pressures of 300-400 bar, the operating pressures should be less than 50% of the maximum capability of the pump (typically < 100-50 bar) (Lachrom HPLC max. pressure 400 bars).

Injection device

Sample introduction is one of the critical steps in HPLC: even the best column will produce a poor separation if injection is not carried out carefully. The most widely used method uses an injection valve (e.g. Rheodyne Model 7010, 7125, or 7410), allowing reproducible volumes to be injected and good quantitative analyses. The sample volume must be about five times the volume of the loop (e.g. 100 μl of sample for a 20 μl loop). This is important for quantitative analysis using an external standard method. An automated injection system (autoinjector) is generally an automated version of the six-port injection valve used for manual injections. With the change of precision syringes, the autoinjector offers a wide range of fully programmable injection volumes (Lachrom HPLC 0.5 - 400 μl). The 25 μl syringe provides the highest accuracy and precision. The autoinjector can be combined with the autosampler permitting unattended injection of samples into the liquid chromatography.

Column hardware

Columns are available in numerous different configurations and from about a hundred different suppliers. The columns vary in dimensions. They are typically 5-25 cm long when micro-particulate stationary phases of 3-10 μm are used. Most HPLC column blanks are made of stainless steel tubes and have compression fittings of various design (e.g. Swagelock, Valco) and steelfrits at either end of the column to retain the column packing material. Stainless steel is resistant to the pressures in HPLC and relatively inert to chemical corrosion.

Column temperature control

The role of temperature is usually neglected in HPLC, and most HPLC separations are carried out at ambient temperature without the aid of a column oven.

Normal-phase HPLC

When the stationary phase is more polar than the mobile phase, the HPLC mode is called normal-phase (NP) chromatography or often adsorption chromatography. NP-HPLC is carried out with inorganic solids such as silica or alumina and various polar bonded phases (e.g. cyano, amino, diol, nitro) which have been reviewed in many sources.

Mixtures of organic solvents are used as the mobile phase such as hexane and dichloromethane.

Reversed-phase HPLC

In the technique of the reversed-phase high-performance liquid chromatography (RP-HPLC) the mobile phase is more polar than the stationary phase which is the opposite of NP-HPLC. The RP methods have traditionally employed hydro-carbon-like stationary phases with polar aqueous organic mobile phases. Compounds are separated according to their relative hydrophobicity, the most polar compounds being eluted first and the non-

polar compounds being retained longer.

Stationary phase

The most commonly used stationary phases for RP separations have been and still are C-18 bonded phases, followed by C-8 and shorter n-alkyl, phenyl, or cyanopropyl bonded phases. Silica has been the most widely used base material for the aforementioned phases.

Mobile phase

It is generally accepted that retention in RP-HPLC is mainly controlled by the mobile phase, with the stationary phase playing the secondary role. Optimum selectivity is usually achieved by finding the right composition for the mobile phase. The preferred organic solvents for the RP-HPLC are methanol (MeOH), acetonitrile (ACN) and tetrahydrofuran (THF), used in binary, ternary, or sometimes in quaternary combinations with water.

Organic solvents are strong and water is a weak solvent. In RP-HPLC solvent strength increases with the decrease in polarity. A change from methanol to acetonitrile or THF can result in significant selectivity changes for various sample solutes.

Isocratic elution is useful, only when toxins with similar retention behaviour are to be studied, whereas gradient elution is effective for the separation of samples containing compounds with a wide variety range of retention times.

Mobile-phase additives

Non-ionic compounds can usually be chromatographed in RP-HPLC in the absence of mobile-phase additives (acids, buffers, ion-pairing reagents, or triethylamine). The pH adjustment usually is performed by using acetic acid (AcOH), phosphoric acid, trifluoroacetic acid (TFA), or different buffers (e.g. sodium or potassium phosphate, ammonium acetate) as mobile phase modifiers.

Reporting retention data

There is yet no qualitative standard method of reporting retention data in HPLC. The methods most in use today are retention times (t_R), retention volumes (V_R), and capacity factors (k') (Eqn 1), which are all strongly sensitive to variations in the chromatographic parameters. Relative retention expressions such as relative retention times (r) (Eqn 2).

$$k' = (t_R - t_o) / t_o \quad (\text{N.B. } t_o = \text{dead time}) \quad (1)$$

$$r = t_{R(x)} / t_{R(st)} \quad (\text{N.B. } x = \text{sample; st} = \text{standard}) \quad (2)$$

Assessment of column efficiency

The ability of a chromatographic process to separate or resolve two similar compounds is measured as the resolution index (R_s) (Eqn 3). The greater the value of R_s the better the resolution of the two compounds. However, values of 1.5 are ideal (Holme and Peck, 1994).

$$\begin{aligned} \text{Resolution } (R_s) &= \frac{\text{twice the distance between the two peaks}}{\text{sum of the base width of the two peaks}} \\ &= \frac{2(t_B - t_A)}{W_A + W_B} \end{aligned} \quad (3)$$

The theoretical plate number (N) is an acceptable measure of the amount of zone broadening occurring in a column (Eqn 4). The greater the value of N the more efficient is the column.

$$\text{Number of theoretical plates } (N) = 5.54 \cdot \frac{(t_R)^2}{(W_{1/2})^2} \quad (4)$$

The height equivalent to a theoretical plate (HETP) may be calculated from the value of N and the column length (L). The HETP is useful in assessing the varying efficiency of the same column under different conditions (Eqn 5).

$$\text{HETP} = L/N \quad (5)$$

Quantitative analysis

Although the response of the detector is usually proportional to the concentration of the test substance it is often impossible to define this relationship precisely and it is essential that the response to a series of standard solution is measured and a calibration factor or curve determined. For external standardization, replicate standards of known concentration of the pure substance are injected and the height or area of the resulting peaks measured.

Detection

The ideal HPLC detector possesses high sensitivity, low minimum detectability, wide linear dynamic range, good linearity and is predictable and fast. Thus far the most commonly used detectors in mycotoxin analysis have been the conventional UV-Vis and fluorescence detectors. The powerful combination of chromatography and spectroscopic techniques have become a reality in HPLC analysis of mycotoxins with the development of diode array detector (DAD) and other interfacing techniques especially thermospray (TSP) and dynamic fast atom bombardment (FAB) allowing HPLC to be coupled online with mass spectrometry (MS). Connecting MS to LC requires an interface device that will convert the liquid phase containing the analytes to a gas phase in the presence of a vacuum.

Compounds that naturally fluoresce or that can be made to fluoresce through chemical derivatisation can be detected with high selectivity and sensitivity by the fluorescence detector. It is about a thousand times more sensitive than a UV detector.

Laser induced fluorescence (LIF) detector offers the most promising application readily distinguishing toxins from a complicated matrix of compounds that do not fluoresce.

3.2.2 HPLC of fumonisin B₁ with OPA derivatisation

(Sydenham *et al.*, 1992B)

3.2.2.1 Apparatus (see Fig. 12)

Liquid chromatograph - Lachrom HPLC (Merck NT)

Autosampler. - x, y, z configuration

Variable Fluorescence detector - Xenon lamp

Computer and printer - with Windows NT 4.0

Data system - HPLC System Manager (D-7 000 HSM).

Column - C 8 Lichrospher (5 μ m) 25 cm x 4 mm (Merck NT).

3.2.2.2 Reagents/solvents

O-phosphoric acid, glacial acetic acid, o-phthaldialdehyde (OPA), 2 - mercaptoethanol, sodium dihydrogen phosphate and disodium tetraborate were analytical grade and obtained from Merck NT except for OPA which was obtained from Sigma. Methanol and acetonitrile were HPLC grade (Merck NT).

3.2.2.3 Mobile phase (MP)

The MP was made up of methanol/ 0.1 M sodium dihydrogen phosphate (68 : 32) and adjusted to pH 3.35 with o -phosphoric acid. Thereafter it was vacuum filtered using a 0.45 μ m Waters HV membrane to remove particulate matter, and degassed by placing it in an ultrasonic bath for 10 minutes.




Fig.12 Lachrom HPLC (Merck NT) used for quantitation of FB_1 .
(Bottom right to top: pump, column,autosampler, UV
detector, fluorescence detector, interface. Left: PC.)

3.2.2.4 Preparation of derivatising reagent

O-phthalaldehyde (40 mg) was dissolved in 1 ml methanol and diluted with 5 ml 0.1 M disodium tetraborate. Fifty μl of 2-mercaptoethanol was then added. The reagent was mixed and kept in a capped amber bottle to be used for one week.

3.2.2.5 Preparation of standards and samples

A stock solution of 50 $\mu\text{g/ml}$ FB_1 standard (Sigma) was made with acetonitrile:water (1:1) and kept in an Eppendorf tube at $-20\text{ }^\circ\text{C}$. A series of dilutions of the stock solution was made, ranging from 4 ng to 0.1 ng/ml FB_1 . Immediately prior to injection onto the HPLC, 50 μl of FB_1 standard was added to 450 μl OPA reagent and mixed. The injection volume was 20 μl .

Dried samples were rehydrated with 200 μl acetonitrile/ water (1:1). Fifty μl of the sample was derivatised by adding 450 μl OPA as above and injected immediately.

3.2.2.6 HPLC set-up

The Lachrom HPLC system was switched on from pump, autosampler, detector, interface and then the computer. The HPLC was initialised via the computer and the method was set up in the D-7000 HSM programme. The detector was set at a excitation of 335 nm and an emission of 440 nm. The system was purged with ultrapure water until the solvent lines were free of air bubbles. Thereafter the HPLC was flushed with water until a steady baseline and pressure was obtained. The pump was stopped and the solvent delivery line A was added to the degassed mobile phase and the system was equilibrated at a flow rate of 1.2 ml/min for FB_1 analyses. A sample table was set up with an injection volume of 20 μl .

3.2.2.7 Quantification

The fumonisin content of the sample is calculated from the chromatographic peak areas as shown below:

$$A \text{ (ng)} = \frac{G \times S}{H}$$

where A = ng of FB₁ present in the sample injected onto the HPLC; G = peak area of the sample; H = peak area of the standard (50 µg/ml); S = amount of FB₁ standard injected onto the HPLC (ng).

$$C \text{ (ng/g)} = \frac{A \times T}{I \times W}$$

where C = the concentration of the FB₁ present in the sample in ng/g or ng/ml;

A = as calculated above; T = total volume of derivatized sample solution (500 µl); I = the injection volume (20 µl); W = the sample equivalent amount derivatized (g or ml).

Simplified:

$$C \text{ (ng/g)} = \frac{A \times 25}{W}$$

3.2.3 HPLC analysis of fumonisin B₁ with FITC derivatisation

(Maragos, 1995)

3.2.3.1 Apparatus

As in section 3.2.2.1, except for fluorescence detection. Excitation was set at 250 nm and emission was 470 nm.

3.2.3.2 Reagents / solvents

Acetic acid, di-methyl sulphoxide (DMSO), 50 mM Borate Buffer pH 9.3 (Merck), 5 - fluoro-isothiocyanate (FITC), acetone and 10 mM Phosphate Buffer pH 7.5 were analytical grade. Acetonitrile and methanol were HPLC grade.

3.2.3.3 Mobile phase

Solvent delivery line A contained degassed methanol (HPLC grade) and solvent delivery line B contained 10mM phosphate buffer, with a pH of 7.5.

3.2.3.4 Preparation of FITC

A 1.3 mM FITC solution was prepared in acetone and kept in an amber bottle in the refrigerator.

3.2.3.5 Preparation of standards

Purified FB₁ were prepared in acetonitrile/water (1:1) (0.2 - 20 µg FB₁ into vials). Four ml methanol with 2% v/v acetic acid was passed through a SAX column and added to each vial above. Standards were dried with nitrogen at 60 °C and dissolved in 500 µl DMSO/ Borate buffer 50 mM, pH 9.5 (9:1). Thereafter 75 µl of FITC was added and the standard mixture was incubated at 60 °C for 90 minutes. This was then cooled to room temperature. Finally 4425 µl of methanol / Borate buffer 50 mM, pH 9.5 v/v (3:2) was added and the standard was ready for HPLC analysis.

3.2.3.6 Gradient elution

The column was equilibrated with 30 % A and 70 % B (see 3.2.3.3). After sample

injection solvent A was increased to 42 % over 7.2 mins., and held at this level until 12 mins. The column was then washed with 90 % A for 4 mins after which the mobile phase was returned to the starting concentration of 30 % A. A mobile phase flow rate of 1 ml/min was used throughout the run.

3.2.4 Capillary electrophoresis (CE) methodology

Capillary electrophoresis employs narrow-bore (20-200 μm internal diameter) capillaries to perform high efficiency separations of both large and small molecules. These separations are facilitated by the use of high voltages ($> 500\text{V/cm}$), which may generate electroosmotic and electrophoretic flow of buffer solutions and ionic species, respectively, within the capillary.

The tube is filled with buffer and subjected to an electric field. Under these conditions, the positive charges migrate toward the cathode at a rate determined by their mass-to-charge ratios. Detection procedures have been based largely on conventional UV absorbance methods, however visible absorbance, UV and fluorescence lasers, and electrochemical detection have been used. The basic instrumental configuration for CE is shown in Fig. 13.

3.2.5 Capillary electrophoresis (CE) of FB_1

3.2.5.1 Apparatus

The instrument used was a Beckman P/ACE System 5000 capillary electrophoresis system, equipped with an Argon-ion laser-induced fluorescence (LIF) detector (laser module 488).




Fig. 13 Basic configuration of the P/ACE Capillary Electrophoresis System.

3.2.5.2 Cartridge

A Beckman 360 604 cartridge housing the capillary (50 cm x 75 μ m i.d) was maintained at 35 °C.

3.2.5.3 Buffer

A 50 mM Borate buffer, pH 9.3 (Electropur grade, Merck NT) was used with a current of 250 μ A provided by 27 kV.

3.2.5.4 Preparation of the FB₁ standard

The standard was prepared as above (3.2.3.5), but diluted at the end (1:20) in electrophoretic buffer.

3.3 Results

3.3.1 Chromatography of FB₁ standards

Chromatograms of standards and solvent blank are shown in Fig. 14 with retention time of FB₁ ranging from 7 to 9 minutes, which was well separated from reagent peaks. Table 3 and Fig.15 show standards analysed with OPA giving a linear response from 0.1 to 4 ng/ml FB₁ with a detection limit of 0.1 ng/ml. Chromatograms of HPLC analysis of FB₁ derivatised with FITC are shown in Fig.16 a . Figure 16 b is an electropherogram from capillary zone electrophoresis (CZE) analysis of FITC derivatised FB₁. The retention time of FB₁ was 16.99 minutes during a run time of 30 minutes. Table 4 shows the comparison of the different techniques used to quantitate




Fig.14 Chromatograms of OPA derivatised FB₁ standards

TABLE 3. FB₁ standards quantitated on HPLC using OPA derivatization

Vol. of stock solution (μl)	Retention time (min.)	Area ($\times 10^6$) (mean \pm SD)	Concentration (ng/ml)
40	8.23	8.398 \pm 0.45	4
30	8.56	6.175 \pm 0.23	3
20	8.06	4.544 \pm 0.31	2
10	7.97	2.083 \pm 0.50	1
5	7.76	1.0 \pm 0.66	0.5
1	7.76	0.205 \pm 0.87	0.103
0.5	7.05	0.399 \pm 0.09	0.05
0.1	6.98	0.266 \pm 0.05	0.01

Fig. 15 Standard curve of OPA derivatised FB1





Fig. 16 HPLC and CZE analysis of FITC derivatised FB₁ (50 µg/ m

16 a Chromatogram

Chrom Type: HPLC Channel : 2



16 b Electropherogram




TABLE 4. Comparison of sensitivity of various procedures used to quantitate FB₁ standards.

CONC.(ng/ml.)	HPLC	HPLC	CZE
	OPA-FB ₁	FITC-FB ₁	FITC-FB ₁
	Peak area	Peak area	Peak area
0.05	0.399	0	0
0.1	0.205	0	0
4	8.398	0	0.489
40	82.054	31.528	4.221
4000	8325.3	3364.9	461.34

fumonisin standards. Retention times and areas indicated in Table 3, are the averages of triplicate runs carried out at different stages of the research. The average pressure of the runs with OPA was 186 ± 7 bars. The pressure during the gradient FITC runs ranged from 170 to 210 bars.

3.3.2 Quantitation of FB₁ in broth culture

The FB₁ produced in chapter 2 were quantitated using HPLC. The positive fractions of broth extract eluted from the column were pooled and cleaned using the Bond-elut columns and then subjected to HPLC analysis as in chapter 2 (Fig. 17). The yield was calculated using the formula (section 3.2.2.7) and was found to be 1.69×10^7 ng/ml of FB₁.




Fig. 17 HPL chromatogram of FB₁ produced in broth culture after 28 days. [OPA derivatisation using methanol / 0.1 M sodium dihydrogen phosphate (68 + 32) pH 3.3, C8 Licrospher (5 μ m), flow rate of 1.2 ml/min.]

3.3.3 Quantitation of FB₁ in patty culture

On HPLC analysis of the 14 extracts of patties, extremely large peaks at retention time of FB₁ (~9 min.) was found and an example of a chromatography is given in Figure 18. This gave a yield of 3.26×10^8 ng/g.

3.4 Discussion

3.4.1 Development of methods of analysis for Fumonisin B₁

High performance chromatography of FB₁ derivatised with OPA and measured by fluorescence detection, showed a linear response from 0.1 to 4 ng/ml and a high level of sensitivity (0.05 ng/ml). Providing that the time taken from derivatisation to injection into the HPLC was constant, the results were reproducible in keeping with the studies done by Thiel *et al.* (1993). In contrast the FITC method of derivatisation was difficult and was not as compatible with HPLC. Phase separation was noted during the derivatisation stage and the HPL chromatograms were cluttered with reagent peaks, which masked the derivatised FB₁, making peak area measurements more difficult. In addition, the OPA derivative of FB₁ gave a larger response in the fluorimeter than the FITC derivative, of around a thousand fold.

On examining these two derivatives by CZE, however, the reverse was true. The FITC derivative of FB₁ gave a detection limit of as little as 4 ng, which agrees with the results of Maragos (1995). This was fifty times more sensitive than the result obtained with the FITC




Fig. 18 Chromatogram of maize patty culture A (5g) showing presence of FB_1 [OPA derivatisation using methanol / 0.1 M sodium dihydrogen phosphate (68 + 32) pH 3.3, C8 Licrospher (5 μ m), flow

derivative on HPLC. This is probably due to the laser-induced detection at 488 nm of the CE which is highly sensitive to FITC derivatives.

These results indicate that for CZE analysis the FITC derivative of FB₁ should be used and for HPLC, the OPA derivative. In this study the OPA derivatisation method was used with HPLC as this was the most sensitive and convenient method overall. The variation in retention times (eg. 7-8 min. with OPA) may be attributed to conditions such as temperature, mobile phase or detector response differing from day to day. An internal control should have been used to work out intra-assay and inter-assay coefficients of variation.

3.4.2 Yield of FB₁ in Broth Culture

The yield of FB₁ was more than 100 times greater than that found by Alberts *et al.* (1994). This high yield of is probably due to the *Fusarium* strain and/or the method of extraction.

3.4.3 Yield of FB₁ in Patty Culture

The yield of FB₁ from maize patty culture was a hundred- fold greater than that produced by *F. moniliforme* PPRI 1059 that was grown on unmodified maize kernels (Nelson *et al.*, 1993; Alberts *et al.*, 1993A) and 10 fold greater than that produced after 13 weeks by the method by Alberts *et al.* (1990). The total amount of FB₁ produced in 420 g (14 plates) of maize patty culture was 137 g giving a yield of 3.26×10^8 ng/g. Thus it can be concluded that the maize patty culture method for the production of FB₁ is better than the broth culture method.

CHAPTER 4

4.0 HIGH-PERFORMANCE LIQUID CHROMATOGRAPHY ANALYSIS OF SERUM OF PRE-ECLAMPTIC/ ECLAMPTIC WOMEN FOR THE PRESENCE OF FUMONISIN B₁

4.1 Introduction

Pre-eclampsia is a disease involving hypertension during pregnancy. It is associated with proteinuria and oedema usually occurring after the 20th week of gestation (Moodley, 1991).

Eclampsia is the severest form of pre-eclampsia resulting in convulsions. Pre-eclamptic hypertension has been found to complicate approximately 7 % of all pregnancies worldwide (Moodley, 1991).

Approximately eighteen percent of all admissions to the King Edward VIII Hospital's obstetric unit have some degree of hypertension (140/90 mmHg) (Moodley, 1991; Maharaj and Moodley, 1994).

Pre-eclampsia is a multi-system disorder which can affect the maternal liver, kidneys, cardiovascular, central nervous and clotting systems as well as can cause impaired placental function (Moodley, 1991). Currently the aetiology of pre-eclampsia is unknown, although various stresses on the patient, both physical and metabolic, have been hypothesised as contributing to the condition.

One possible source of metabolic stresses is related to diet, which can include an imbalance of nutrients and vitamins and the possible presence of toxic contaminants. Maize, the staple diet of most South African Black women, is often contaminated with mould such as *Fusarium moniliforme*, a mycotoxin producer. This mould abundantly produces one of six known fumonisin toxins, namely, fumonisin B₁ (FB₁). Global levels of FB₁ in maize, range from 30 to 334 000 ug/kg (Dutton, 1996). Animal models have shown FB₁ to be hepatotoxic and hepatocarcinogenic in rats (Gelderblom *et al.*, 1995), to cause leukoencephalomalacia (ELEM or 'hole in the head' disease) in horses (Wilkins *et al.*, 1994; Thiel *et al.*, 1991) and pulmonary oedema in pigs (Tibor, 1995). Statistical analysis has associated FB₁ in home-grown maize among the rural population of the Transkei, South Africa, with oesophageal cancer (Sydenham *et al.*, 1990).

Fumonisin B₁ is the diester of propane -1,2,3-tricarboxylic acid and 2-amino-12,16-dimethyl-3,5,10,14,15-pentahydroxicosane, in which the C₁₄ and C₁₅ hydroxyl groups are esterified with one of the terminal carboxy groups of the tricarboxylic acid (Dutton, 1996). The structure of the backbone of the fumonisin molecule was found to be similar to the important phospholipid, sphingosine (Fig.1) (Wang *et al.*, 1992). Animal cell culture experiments have shown that FB₁ are potent inhibitors of sphingolipid biosynthesis (Norred *et al.*, 1997). Fumonisin B₁ was found to cause an accumulation of sphinganine and a paralleled increase in DNA synthesis in Swiss 3T3 fibroblasts. Fumonisin B₁ was also found to inhibit protein synthesis (Merrill *et al.*, 1996) and inhibit the secretion of ceramide into very low density lipoprotein (Merrill *et al.*, 1995).

Common symptoms of FB₁ intoxication in animals appear to be oedema (Harrison *et al.*,

1990), lesions (Kellerman *et al.*, 1990), haemorrhages (Bucci *et al.*, 1996) and other cellular changes in the liver (Norred *et al.*, 1997; Voss *et al.*, 1998) and kidney(Bucci *et al.*, 1998). The foetus in pregnant rats were also affected causing low litter weights and fetal bone development (Ferguson *et al.*, 1997). Pregnant mice fed with fumonisins showed lowered body weights, increased morbidity and mortality in a dose response way (Gross *et al.*, 1994) . Liver damage and increased foetal deaths were also found (Voss *et al.*, 1998).

In vivo vervet monkey experiments indicate a lower level of excretion of FB₁ and its partly hydrolysed derivatives after intra-peritoneal (ip) injection than in the case of rats (almost 90%) (Shephard *et al.*, 1992A). At least a quarter of the toxic material fed to primates could not be accounted for. Thus there is the possibility that the toxin may be absorbed by the blood in varying proportions in different species of animals, including man. The time-delay of excretion of toxin may also vary.

There is a high incidence of both consumption of FB₁ contaminated maize by Black women, and pre-eclampsia, in Kwa-Zulu Natal. Thus this study sought to hypothesize that an association exists between the incidence of FB₁ serum levels and pre-eclampsia. A double-blind study was carried out involving normotensive, pre-eclamptic and eclamptic patients of the King Edward VII Hospital. Serum was analysed by fluorescence HPLC (Shephard *et al.*, 1992A).

4.2 Method

4.2.1 Study population and sample collection

This study was conducted at the King Edward VII Hospital, Durban, South Africa following institutional ethical approval. The sample which was provided blind comprised normal pregnant women (16), pre-eclamptic (PEC) women (17) and eclamptic (EC) women (18) attending the obstetric clinic. Informed consent was obtained from the patients. The blood samples were collected intravenously and centrifuged with EDTA resulting in the separation of plasma from the serum supernatant. The sera were stored in cryovials at -20°C .

4.2.2 Extraction and clean up of serum

A variety of extraction and clean-up methods for mycotoxins have been employed by several authors. Since mycotoxins occur in a wide variety of commodities and products, the extraction from a sample depends on the physicochemical properties of the sample as well as the toxin. In general, the sample is subjected to high-speed blending, mechanical shaking or centrifugation in the presence of the extraction solvent system. The slurry is then filtered and is ready for subsequent purification procedures. The most efficient solvents for extracting mycotoxins are the relatively polar solvents such as methanol, acetone, acetonitrile, ethyl acetate, and chloroform. Fumonisin extraction is characteristically carried out in methanol/water (3:1) solvent mixtures. The water wets the substrate and increases penetration of the solvent mixture into the hydrophilic material.

The aqueous phase can include acid to break interaction between the toxin and proteins for example. Inorganic salts (eg. NaCl) may be added to minimize the formation of emulsions during the extraction.

Other clean-up methods include column chromatography, liquid-liquid extraction and commercially available solid-phase extraction (SPE) and chromatography cartridges. The final step prior to analysis of the sample involves concentration of the cleaned-up extract. This is performed using a rotary evaporator operating under reduced pressure or a steam bath under a stream of nitrogen for concentration of the sample.

Serum (1 ml) was de-proteinised by centrifuging with 7.5 ml methanol at 1 200 g for ten minutes at 20 °C. The supernatant was collected and applied to a solid- phase extraction cartridge, Bond-elut strong anion exchange (SAX) cartridge (Varian) at a flow rate of 1 ml/minute. The cartridge was pre-conditioned with 5 ml of methanol (HPLC grade, Merck) and 5 ml methanol/ water v/v (3:1) (Fig. 19) . The cartridge was washed with 5 ml of methanol/ water v/v (3:1) and 5 ml methanol. The sample was eluted with 10 ml of 5 % acetic acid (Analar grade, Merck) in methanol at a flow rate of 1,0 to 1,5 ml / minute. The eluate was dried under nitrogen at 60 °C.

4.2.3 Derivatisation and HPLC analysis

Standard and sample residues were derivatised using the o-phthalaldehyde (OPA) reagent (Shephard *et al.*, 1994). A 50 µg/ml FB₁ standard solution in acetonitrile/water (1:1) was prepared and 50 µl was transferred to an autosampler vial. The purified sample




Fig. 19 Solid-phase extraction (Bond-elut) of fumonisins from serum

residue was redissolved in 200 μ l of acetonitrile/ water v/v (1:1) and 50 μ l of this was added to a vial. Both the standard and the samples were each derivatised by adding 450 μ l of the OPA reagent. The solutions were mixed and subjected to immediate HPLC analysis (20 μ l) on the Lichrosorb 5 μ m C 8 reverse phase column (25 cm x 4 mm) (Merck). Peaks were detected using a Lachrom variable fluorescent detector (Merck) set at 335 nm (excitation) and 440 nm (emission). The mobile phase used was HPLC grade (Merck) methanol / 0.1 M sodium dihydrogen phosphate (68+32), pH of 3,3 held at a flow rate of 1,2 ml/minute. Each serum sample was analysed in duplicate. Quantification of FB₁ content of serum sample was calculated from the chromatographic peak areas using the formula described by the PROMEC group (Thiel *et al.*, 1993) (see section 3.2.2.7).

4.2.4 Recovery by Bond-elut SAX columns

Recovery studies were done where 1 ml of serum samples (not from Black women) , shown to be free of FB₁, were spiked with 50 μ g/ml FB₁ standard solution (2 to 8 μ l) and analysed by HPLC as above.

4.2.5 Verification of FB₁ by immunoaffinity columns

Immunoaffinity chromatography is a powerful and specific use for the separation and / or purification of biological compounds. The desired material binds specifically and reversibly to a ligand which has been fixed to an inert carrier. Ligands range from small molecules such as substrates for enzymes or mycotoxins to large molecules such as protein hormones. The introduction of a binding site with a ligand is determined by the overall size

and shape of the ligand as well as the number and distribution of complementary surfaces. These surfaces may involve a combination of charged and hydrophobic moieties and exhibit other short range molecular interactions such as hydrogen bonds and Vander Waals forces (Betina, 1993).

The method was similar to that of Ware *et al.* (1994). Selected serum samples (1 ml) were applied to immuno-affinity columns, the Fumonitests (Vicom) after spiking with fumonisin B₁ standard (Sigma). Eclamptic sera were also cleaned with the Fumonitest columns. After de-proteinisation, 5 ml of serum supernatant was passed through the column at a flow rate of 1 ml/min. Five ml of diluting solution (2.5 % NaCl, 0.5 % Na₂CO₃, 0.01 % Tween-20 in water) was passed through the column at a flow rate of 2-4 ml/min.. The column was washed with 5 ml of water. The absorbed FB₁ was eluted with 1 ml methanol (HPLC grade, Merck NT). The eluate was dried under nitrogen and analysed by HPLC as previously described.

4.2.6 Verification of the presence of FB₁ in serum by Mass spectroscopy

The Finnigan LCQ mass spectrometer (MS) was operated in the electrospray ionization (ESI) mode with a capillary temperature of 220 °C and the sheath gas was nitrogen at 80 ml/min. Fumonisin B₁ was detected in the positive ion mode using 1 % acetic acid in water at a flow rate of 3 µl/min. Qualitative analysis was carried out using the external standard method.

Serum samples were analysed for the presence or absence of FB₁. The serum samples were

treated with Bond-elut SAX as before. The samples were reconstituted in acetonitrile/water v/v (1: 1) before injection.

4.2.7 Statistical tests

Non-parametric tests were carried out at the Department of Biostatistics at the University of Natal in Durban, on the serum results and the clinical data of the women, owing to an absence of a normal distribution in the data.

4.3 Results

Fifty- one pregnant women comprised the study, and upon completion of the HPLC analysis, the study was unblinded. Three sample groups were identified according to their level of blood pressure. The clinical characteristics of the women are summarised in Table 5. No significant difference was found between the normal (29.8 ± 1.5 ; range 18-40 years) and pre-eclamptic (27.5 ± 1.9 ; range 18-45 years) groups with regard to age. However, a significant difference was noted between the pre-eclamptic and the eclamptic groups (19.8 ± 1.5 ; range 13-38 years). Parity and gravidity increased with increasing hypertension. Highly significant differences were noted in parity and gravidity between the normal and eclamptic groups ($P = 0.001$ and $P = 0.0004$ respectively). Gestational age was similar in all groups.

Chromatograms indicate that the FB_1 standard ($20 \mu\text{g/ml}$) peak occurred at a retention time (t_R) of approximately 7.5 minutes (Fig.20 a). The FB_1 peak was absent in most of the

normal sera (Fig. 20 b). In the eclamptic sera 3 peaks were found to represent fumonisin, namely FB₁

Table 5. Obstetric and epidemiological characteristics of the three groups of women tested. Values are given as mean (SE).

Variable	Normal	Pre-eclamptic	Eclamptic	P value		
	n=16	n=17	n=18	N/PE	N/E	PE/E
Age (yrs.)	29.8(1.5)	27.5(1.9)	19.8(1.5)	0.3	0.0007	0.08
Parity	2.6(0.4)	1.4(0.4)	0.7(0.4)	0.05	0.001	0.1
Gravidity	3.8(0.4)	2.4(0.3)	1.7(0.4)	0.01	0.0004	0.1
Gestational age (years)	35.1(1.4)	33.8(1.9)	33.6(1.0)	0.6	0.15	0.3
DBP (mmHg)	80.0(3.0)	98.7(2.3)	115.6(3.3)			
SBP (mmHg)	113.2(1.7)	148.6(2.7)	183.2(8.1)			
Proteinuria	0.2(0.2)	0.6(0.3)	2.3(0.3)			

N = Normal, PE = Pre-eclamptic and E = Eclamptic.

DBP = diastolic blood pressure, SBP = systolic blood pressure.




Fig.20 HPL chromatograms showing presence of FB₁ and HFB₁. [OPA derivatisation using methanol / 0.1 M sodium dihydrogen phosphate (68 + 32) pH 3.3, C8 Lichrospher (5 μ m), flow rate of 1.2 ml/min.]

($t_R = 7.04$ minutes) and its 2 hydrolysed products (HFB₁), ($t_R = 8.14$ and 9.33 minutes, Fig. 20 c). The areas under the peaks were used to calculate the FB₁ concentration in sera (Table 6). An average recovery of 95 % was obtained for spiked sera over the range 0.1 to $0.4 \mu\text{g/ml}$. The concentration of FB₁ was corrected for recovery (Table 6). The spiked sera passed through the Fumonitest columns gave peaks between 7 and 10 minutes. The calculated concentration of FB₁ was almost equivalent to that obtained when sera was cleaned with SAX columns (Table 7). Unspiked eclamptic sera that were cleaned with Fumonitest columns also produced FB₁ and HFB₁ peaks in the region 7-10 minutes .

Electrospray MS was an ideal technique to detect FB₁. Fumonisin B₁ tended to be ionic and produced abundant signals in the positive ion mode. In the positive mode, the protonated molecule (m/z 722 for FB₁) is the base peak in the mass spectrum (Fig.21). Analysis of serum samples are indicated in Table 8. The two maternal sera tested indicated the presence of FB₁ verifying the presence of FB₁ in pre-eclamptic women (Fig. 22).

Statistical tests indicate a significant difference between the normal ($0.32 \pm 0.08 \mu\text{g/ml}$) and eclamptic ($2.85 \pm 0.80 \mu\text{g/ml}$) groups and the pre-eclamptic ($0.45 \pm 0.17 \mu\text{g/ml}$) and the eclamptic groups with regard to mean FB₁ concentration (Fig.23).

Table 6. Concentration of FB₁ in the three groups of sera tested.

	NORMAL (N = 16)	PRE-ECLAMPSIA (N = 17)	ECLAMPSIA (N = 18)
Concentration of FB₁ in serum samples (μg/ml)	0.03 0.55 0.6 0.06 0.09 0.68 0.65 0.86 0 0.06 0 0.63 0 0.01 0.31 0.37	0.3 0.09 0 0.63 2.19 0 2.23 0.11 0.11 0.19 0.13 0.07 0.5 0.09 0.08 0.27 0.2	3.41 4.58 3.17 0.45 0.6 1.2 1.4 3.8 13.29 7.15 5.35 0.96 1.22 0.51 0.16 0.72 0.62 0.07
Mean Conc. of FB₁ after SAX (μg/ml)	0.31	0.42	2.7
Mean Conc. +/- Std error of FB₁ corrected for 95 % recovery (μg/ml)	0.32 +/- 0.08	0.45 +/- 0.17	2.85 +/- 0.8

Table 7. Comparison of clean-up procedures of FB₁ from sera.

Conc. of FB ₁ spiked in sera (µg/ml)	SAX chromatography	Affinity chromatography
1.0	0.942	0.968
0.5	0.463	0.478
0.1	0.094	0.096

Table 8. Clinical data of serum samples tested on Mass Spectroscopy

SAMPLE	1	2	3	4
Source	placenta	placenta	maternal	maternal
Age (years)	24	23	24	19
Blood pressure	130/80	130/60	140/90	197/108
Parity / Gravidity	P2 G3	P0 G1	P0 G1	P0 G1
Pregnancy stage (weeks)	38	term	(C- section)	34
Fumonisin B ₁	NO	NO	YES	YES




Fig. 21 ESI mass spectrum of FB₁.
(Note the base peak of FB₁ at m/z 722)

: 1-60 RT: 0.03-2.52 AV: 60 NL: 6.48E1
+ c ms [200.00 - 2000.00]




Fig. 22 ESI mass spectrum of serum of a pregnant woman.
(Note the base peak of FB₁ at m/z 722)




Fig. 23 Fumonisin B₁ concentration in sera of pregnant woman.

4.4 Discussion

The results from this study are not only remarkable but unexpected in that animal studies have shown the absorption of fumonisins from the diet to be very low (1.0 %) (Shephard *et al.*, 1994A; Norred *et al.*,1996). Blood levels return to near zero after 48 hours from administration in the rat. This trend seems to be similar in other species investigated, e.g., in the monkey (Shephard *et al.*, 1994B) where fumonisin is rapidly excreted in the faeces together with unabsorbed material. If humans have a comparable absorption of FB₁ to the rat, then the levels in the food (assumed to be principally maize) that the patient has consumed would have to be $\mu\text{g/g}$. Furthermore this does not allow for time between ingestion of FB₁ and sampling of the blood which was done in the hospital. Analysis of rural and animal feed maize from Kwa-Zulu Natal does indicate the ubiquitous occurrence of FB₁ which is in over 50 % of the samples. The highest concentration measured was 120 $\mu\text{g/g}$ which compares with that found by the PROMEC group (Sydenham *et al.*, 1991) in mouldy maize for beer brewing in the Transkei, South Africa in 1989. Continual ingestion of maize with levels of FB₁ of this order, coupled with malnourishment and vitaminosis could explain these results.

From the analytical point of view, the appearance of peaks in the chromatograms of serum extracts, subjected to the assay method , with the t_R of 7.04 minutes (Fig. 20 c) for FB₁ is not conclusive in that they cannot be assigned with absolute certainty as the toxin. Support of the identity of the peaks as being FB₁ was obtained when unspiked eclamptic serum samples showed that the FB₁ peaks were coincident with the peak t_R of approximately 7 minutes. As the immunoaffinity columns are specific for fumonisins, this result serves to

confirm the presence of FB₁ in the serum of the women investigated. The eluted FB₁ fraction from these gave comparable results to those from SAX columns (Table 7). Recovery experiments using spiked samples showed that the extraction of FB₁ from serum is good even at low concentrations. Some of the serum extracts were also subjected to an ELISA assay being developed in this laboratory (P.Biden). Although the ELISA method is not at a stage where quantitation of FB₁ in serum is precise, the results did broadly agree with those derived by HPLC thereby confirming the presence of FB₁ in eclamptic sera . The presence of FB₁ in sera of pregnant women was also confirmed by ESI MS (Fig. 21 and 22). It also happens that the two serum samples testing positive for FB₁ on MS are of the lower age group (19-24 years) and also have a very high blood pressure (Table 8). This agrees with the results obtained with the HPLC analysis of the 51 sera of pregnant women tested.

As the results show a statistical difference between normal, pre-eclamptic and eclamptic sera, it is tempting to speculate that FB₁ has some role to play in the aetiology of eclampsia. The finding of higher levels of the toxin in women with eclampsia, in itself, is not proof of its aetiological effect . Other possibilities exist, not least that they are purely coincidental, e.g. a poor diet is the contributory factor and FB₁ is a marker of that. A major difficulty is to distinguish between cause and effect. Thus the results might be showing that women with pre-disposition to eclampsia poorly excrete the toxin and it accumulates and circulates in the blood system. Thus it is possible that high levels of FB₁ is due to other organ damage, e.g. the kidney and liver, as is suggested by patients records. Although 90% of fumonisin intake by animals is normally excreted (Shephard *et al.*, 1994B) pre-eclamptic women, who often show renal and liver dysfunction (Randeree, 1995), may have difficulty

with the ready excretion of the toxin. Thus the accumulating of FB₁ in the serum of pre-eclamptic women. The high toxin levels may be secondary to organ damage rather than a factor in the aetiology of pre-eclampsia or eclampsia.

If, however, it is accepted that FB₁ does have something to do with the disease, then explanations for two questions are possible. The first one is, why pre-eclampsia and eclampsia are so common in the eastern seaboard of South Africa? This is the area where maize is the main food staple and the conditions are right for extensive contamination of the crop by *F. moniliforme* and the production of FB₁ and other fumonisins. The second is that a standard treatment for pre-eclampsia is the administration of magnesium sulphate and calcium (van den Elzen *et al.*, 1996). Fumonisin is known to be polycationic and binds calcium and sodium, which in fact contributes to its poor uptake in the GIT (Shepherd *et al.*, 1994). It is likely that magnesium and calcium ions administered after FB₁ uptake sequester it in the blood, perhaps rendering it more amenable to excretion by the kidney and also preventing it from binding to cells and being taken up by its normal site of action (van den Elzen *et al.*, 1995).

The toxicokinetic data generated by the intravenous injection of FB₁ in vervet monkeys show that the elimination of fumonisin from the plasma can be characterised by an initial distribution phase and a subsequent elimination phase with a mean half-life of 40 minutes. This is approximately twice that in rats. Hydrolysed products of fumonisins were also found in the liver gut and kidney of monkeys in varying proportions (Shepherd *et al.*, 1994B).

Since the patients were outpatients attending the clinic in the morning they were likely to

have consumed an early breakfast of contaminated maize meal. This may explain the high levels of fumonisins in their serum.

On the assumption that FB₁ is a factor in South African eclampsia, there is a need to speculate about its mode of action. Pre-eclampsia is relieved at birth and expulsion of the placenta, thus it may be speculated that the toxin interferes with sphingolipid biosynthesis, or signalling dependent upon sphingolipid in the placental tissue. Fumonisin is known to cause apoptosis in cells (Reddy *et al.*, 1996; Sharma *et al.*, 1997), which reflects interference in these mechanisms. Such activity within placental tissue would lead to pathological disturbances within the patient. In addition to the above, animal fumonisin intoxication and eclampsia share many common symptoms (Espada *et al.*, 1997; 1996; Barker *et al.*, 1995; Fields *et al.*, 1994), such as hepatic damage, cerebral oedema, pulmonary oedema, proteinuria, low serum albumin, foetal malformation and alteration of hemostasis.

4.5 Conclusion

Eclamptics have a higher level of FB₁ in serum than pre-eclamptics and normal pregnant women. This indicates that the presence of FB₁ in pregnant women may be a contributory factor towards eclampsia and perhaps pre-eclampsia. A thorough dietary profile of these patients needs to be done to confirm the causal effect of fumonisin B₁ in the above diseases. In addition, sera should be analysed for a specific biomarker (sphinganine/sphingosine ratio) for the possible implication of FB₁ in eclampsia and pre-eclampsia.

APPENDIX 1**LIST OF REAGENTS AND BUFFERS**

1. o-phythaldialdehyde (OPA)
2. 5-fluoro-isothiocyanate 1.3 mM
3. Borate buffer 50 mM pH 9,3
4. Phosphate buffer 10 mM pH 7,5
5. 0,01% Tween -20 in water

APPENDIX 2**LIST OF ABBREVIATIONS**

1. HPLC : high performance liquid chromatography
2. FB₁ : fumonisin B₁
3. TLC : thin layer chromatography
4. MS : mass spectroscopy
5. IA : immunoassay
6. CE : capillary electrophoresis
7. OPA : o-phythaldiadehyde
8. FITC : 5-fluoro-isothiocyanate
9. SE : standard error
10. SAX : strong anion exchange
11. BMA : butanol / methanol / acetic acid
12. PROMEC : programme on mycotoxins and experimental carcinogenesis

SUMMARY

The serious pathological effects of fumonisins on plants, animals and humans have been established by numerous researchers thus far. The case for human pathology caused by fumonisins has not however been strong, owing to the ethical and practical implications of such studies. This study has found a positive correlation between the amount of FB₁ in serum and the severity of pre-eclampsia. This may have been caused by dietary exposure to *Fusarium* contaminated maize, its various products and many other important foods. This is in keeping with findings by Shephard *et al.* (1994B) who found that although most of FB₁ dosed to primates were excreted within 48 hours, 25 % of the dosage was not accounted for. Perhaps they were absorbed and found their way to various parts of the body such as the liver. In this study significantly high levels of FB₁ were found in sera of eclamptic women. These women present various pathophysiological effects which are very similar to that found in animals intoxicated by fumonisins. HPLC analysis of culture material and sera were highly efficient in quantitating FB₁ at low levels and the OPA derivatisation procedure is recommended. However if a biomarker is required to confirm the pathophysiological effects of fumonisins in humans, then use must be made of HPLC techniques that quantitate sphingosine in biological fluids.

REFERENCES

- Abbas HK and Ocamb CM. First report of production of fumonisin B₁ by *Fusarium polyphialidicum* collected from seeds of *Pinus strobus*. *Plant dis.* 1995; **79** : 642.
- Abeywickrama K and Bean GA. Effects of fumonisins and *Fusarium moniliforme* culture extracts to a baby hamster kidney cell line. *Phytopath.* 1992; **82** : 718-720.
- Abouzied M M, Pestka JJ. Simultaneous screening of fumonisins B₁, aflatoxin B₁ and zearalenone by line immunoblot: a computer assisted multianalyte system. *J Assoc Off Anal Chem Internat* 1994; **77**: 495-500.
- Ackerman T. Fast thin layer chromatography systems for fumonisin isolation and identification. *J Appl Toxicol* 1991; **11**: 451-454.
- Akiyama H, Miyahara M., Toyoda M. and Saito T. Liquid chromatographic determination of fumonisin B₁ and B₂ in corn by precolumn derivatization with 4-(N,N-dimethylaminosulfonyl)-7-fluoro-2,1,3 benzoxadiazole. *J Food Hyg Soc Jap* 1995; **36** : 77-81.
- Akiyama H, Uraroongroj M, Miyahara M, Goda Y, Hoyoda M. Quantitation of fumonisins in corn by hplc with o-phthalaldehyde post column derivatisation and their identification by LC/MS. *Mycopath* 1998; **140**: 157-161.
- Alberts JF, Gelderblom WCA., Thiel PG, Marasas WFO, van Schalkwyk DJ and Behrend Y. Effects of temperature and incubation period on production of fumonisin B₁ by *Fusarium moniliforme*. *Appl Environ Microbiol* 1990; **56**: 1729-1733.
- Alberts JF, Gelderblom WCA, Vleggaar R, Marasas WFO and Rheeder JP. Production of fumonisin B₁ by *Fusarium moniliforme* MRC 826 in corn cultures. *Environ Microbiol* 1993A; **59**: 2673-2677.
- Alberts JF, Gelderblom WCA and Marasas WFO.. Evaluation of the extraction and purification procedures of the maleyl derivatization HPLC technique for the quantification of the fumonisin B₁ mycotoxins in corn cultures. *Mycotoxin Res* 1993B; **9**: 2-12.
- Alberts JF, Gelderblom WCA, Marasas WFO and Rheeder JP. Evaluation of liquid media for fumonisin production by *Fusarium moniliforme*. *Mycotoxin Res* 1994; **10**:107-115.
- Allah EMF. Occurrence and toxicity of *Fusarium moniliforme* from freshly harvested maize ears with special reference to fumonisin production in Egypt. *Mycopath* 1998; **140**: 99-103.

- Anthony J, Johanson RB and Duley L. Role of magnesium sulfate in seizure prevention with eclampsia and pre-eclampsia. *Drug Saf* 1996; **15**(3): 188-99.
- Bacon CW, Porter JK and Norred WP. Toxic interactions of fumonisin B₁ and fusaric acid measured by injection into fertile chicken egg. *Mycopath* 1995; **129**: 29-35.
- Badiali L, Abou-Youssef HA, Radwan AI, Hamdy FM and Hilderbrandt PK, Moldy corn poisoning as the major cause of encephalomalacia syndrome in Egyptian equidae *Am J Vet Res* 1968; **29**: 2029-2035.
- Badria FA, Abbas HK and Shier WT. Chemical transformation of hydrolyzed fumonisin B₁ to hydrolysed fumonisin B₂. *J Agric Food Chem* 1995; **43**: 1989-1992.
- Baker PN. Possible dietary measures in the prevention of pre-eclampsia and eclampsia. *Baillieres Clin Obstet & Gynec* 1995; **9**(3): 497-507.
- Becker BA, Pace L, Rottinhaus GE, Shelby R, Misfeldt M and Ross PF. Effect of feeding fumonisin B₁ in lactating sows and their suckling pigs. *Am J Vet Res* 1995; **56**: 1253-1258.
- Beek van E and Peeters LLH. Pathogenesis of pre-eclampsia: a comprehensive model. *Obstet & Gynec Survey* 1998; **53**(4): 233-241.
- Beier RC and Stanker LH. Molecular modules for the stereochemical structures of fumonisin B₁ and B₂. *Arch Environ Contam Toxicol* 1997; **33**: 1-8.
- Bennett and Richards. Liquid chromatographic methods for analysis of the naphthalene dicarboxaldehyde derivative of fumonisins. *J Assoc Off Anal Chem Internat* 1994; **77**: 501-506.
- Bermudez AJ, Ledoux DR, Rottinghaus GE and Bennett GA. The individual and combined effects of the *Fusarium* mycotoxins moniliformin and fumonisin B₁ in turkeys. *Avian Dis* 1997; **41**(2): 304-11.
- Bettina V. Chromatography of mycotoxins. *J Chromatog. Lib.* 1993; **54**:46-101.
- Bezuidenhout SC, Gelderblom WCA, Gorst-allman RMM., Marasas WFO, Spiteller G and Vleggaar R. Structure elucidation of the fumonisins, mycotoxins from *Fusarium moniliforme*. *J C S Chem Comm* 1988; 743-745.
- Bhat RV, S PH, Amruth RP and Sudershan RV. A food borne disease outbreak due to the consumption of moldy sorghum and maize containing fumonisin mycotoxins. *Clin Toxicol* 1997; **35**: 249-255.
- Bondy G, Suzuki C, Barker M., Armstrong C, Ferni S, Hierlihy L, Rowsell P and Mueller R. Toxicity of fumonisin B₁ administered intraperitoneally to male Sprague-Dawley rats. *Food Chem Toxicol.* 1995; **33**: 653-665.

- Bondy GS, Suzuki CA, Fernie SM, Armstrong CL, Hierlihy SL, Savard ME and Barker MG. Toxicity of fumonisin B₁ to B6C3F1 mice: a 14 day gavage Sprague-Dawley rats. *Food Chem Toxicol* 1997; **35(10-11)**: 981-989.
- Bottalica A, Logrecos A., Ritien A, Morettis A, Randazza G and Corda P. Beauvaricin and fumonisin in preharvest *Fusarium moniliforme* maize ear rot in Sardinia. *Food Add Contam* 1995; **12**: 599-607.
- Boyle and Kishi. Absolute configuration at the tricarballic acid moieties of fumonisin B₁ and AAL toxin TA. *Tet Letts* 1995B; **36**: 5695-5698.
- Branham RDA and Plattner RD. Alanine is a precursor in the biosynthesis of fumonisin B₁ by *Fusarium moniliforme*. *Mycopath* 1993; **124**: 99-104.
- Bragulat M.R, Abarca ML, Castella G and Cabanese FJ. Fungi and mycotoxins in grain - implications for stored food product research. *J Stored Prod Res* 1995A; **31**: 1-16.
- Brown MA and Buddle ML. Hypertension in pregnancy:maternal and fetal outcomes according to laboratory and clinical features. *Med J of Australia* 1996; **165(7)**: 360-365.
- Bucci TJ, Hansen DK, and Laborde JB. Leukoencephalomalacia and hemorrhage in the brain of rabbits gavaged with mycotoxin fumonisin B₁. *Nat Toxins* 1996; **4**: 51-52.
- Bucci TJ, Howard PC, Tolleson WH, Laborde JB. Hansen DK. Renal effects of fumonisin mycotoxins in animals. *Toxicol Path* 1998; **26**: 160-164.
- Buck WB, Haliburton JC, Thilsted JP, Lock TF and Vesonder RF. Equine leukoencephalomalacia: comparative pathology of naturally occurring and experimental cases. *Amer Assoc Vet Lab Diagnos 22nd Ann Proc* 1979; 239-258.
- Bullerman LB and Tsai WJ. Incidence and levels of *Fusarium moniliforme*, *Fusarium proliferatum* and fumonisins in corn and corn-based foods and feeds. *J Food Protect* 1994; **57**: 541.
- Burrell RJW. Oesophageal Cancer in the Bantu. *SA Med J* 1957; **31**: 401-409.
- Caldas ED, Jones AD, Winter CK, Ward B and Gilchrist DG. Electrosprayionization mass spectrometry of sphinganine analog mycotoxins. *Anal Chem* 1995; **67**: 196-207.
- Campbell GD.Mycotoxycosis--humankinds greatest affliction. *Nut & Health* 1996; **10(4)**: 323-329.
- Caramelli M, Dondo A, Cortellazzi GC, Visconti A, Minervini, F, Doko MB and Guarda F. Leukoencephalomalacia in the equine caused by fumonisins: first report in Italy. *Ippologia* 1993; **4**: 49-56.

- Casteel SW, Turk JR, Cowart RP and Rottinghaus GE. Chronic toxicity of fumonisin in weanling pigs. *J Vet Diagn Invest* 1993; **5**: 413-417.
- Casteel SW, Turk JR and Rottinghaus GE. Chronic effects of dietary fumonisin on the heart and pulmonary vasculature of swine. *Fund Appl Toxicol* 1994; **23**: 518-524.
- Cawood ME, Gelderblom WCA, Vleggaar R, Behrend Y, Thiel PG and Marasas WFO. Isolation of the fumonisin mycotoxins : A quantitative approach. *J Agric Food Chem* 1991; **39**: 1958-1962.
- Cawood ME, Gelderblom WCA, Alberts JF and Snyman SD. Interactions of ¹⁴ C- labelled fumonisin B₁ mycotoxins with primary rat hepatocyte cultures. *Food Chem Toxicol* 1994; **32**: 627-632.
- Chatterjee D and Mukherjee SK. Contamination of Indian maize with fumonisin B₁ and its effects on chicken macrophage. *Letts Appl Microbiol* 1994; **18**: 251-253.
- Chelkowski J, Visconti A, Dokko B and Wisniewska H. *Fusarium moniliforme* Sheldon: pathogenicity to wheat seedlings and ability to produce fumonisins. *Phytopathologische Zeitschrift* 1995; **143**: 491-493.
- Cheng AY and Kwan A. Perioperative management of intra-partum seizure. *Anaesthesia & Intensive Care* 1997; **25(5)**: 535-8.
- Chu FS and Li GY. Simultaneous occurrence of fumonisin B₁ and other mycotoxins in moldy corn from the Peoples Republic of China in regions with high incidence of oesophageal cancer. *Appl Environ Microbiol* 1994; **60**: 847-852.
- Churchwell MI, C WM, Howard PC and Doerge DR. Determination of fumonisins in rodent feed using hplc with electrospray mass spectrometric determination. *J Agric and Food Chem* 1997; **45**: 2573-2578.
- Colvin BM and Harrison LR. Fumonisin-induced pulmonary edema and hydrothorax in swine. *Mycopath* 1992; **117**: 79-82.
- Colvin BM., Cooley AJ and Beaver RW. Fumonisin toxicosis in swine: clinical and pathologic findings. *J Vet Diagos Invest* 1993; **5**: 232-241.
- Dawlatana M, Coker RD, Nagler MJ and Blunden G. A normal phase HPTLC method for the quantitative determination of fumonisin B₁ in rice. *a Chromatographi* 1995; **41**: 187-190.
- Desjardins AE, Plattner RD and Nelson PE. Production of fumonisin B₁ and moniliformin by *Gibberella fujikuroi* from rice from various geographic areas. *Appl Environ Microbiol* 1997; **63**: 1838-1842.
- Doko MB and Visconti A. Occurrence of fumonisin B₁ and B₂ in corn and corn-based

- human foodstuffs in Italy. *Food Add Contam* 1994; **11**: 433-439.
- Doko MB, Rapior S, Visconti A. and Schjoth JE. Incidence and levels of fumonisin contamination in maize genotypes grown in Europe and Africa.. *J Agric Food Chem* 1995; **43**: 429-434.
- Dombrink-Kurtzman MA, Javed T, Bennett GA Richard JL, Cote LM and Buck WB. Lymphocyte cytotoxicity and erythrocytic abnormalities induced in broiler chicks by fumonisin B₁ anaB₂ and moniliformin from *Fusarium proliferatum*. *Mycopath* 1993; **124**: 47-54.
- Domenech J, Boccas B, Pellegrin F, Laurent D, Kohler F, Magnol, J and Lambert C. *Fusarium moniliforme* fusariosis of maize in New Caledonia and related equine pathology: toxic leukoencephalomalacia. *Rev Ele Med Vet Pays Trop* 1984; **37**: 253- 259.
- Dowling TS. Fumonisin and its Toxicity. *Cer Food World* 1997; 13-15.
- Dupuy J, Le Bars P, Boudra H. and Le Bars J. Thermostability of fumonisin B₁ , a mycotoxin from *Fusarium moniliforme* in corn. *Appl Environ Microbiol* 1993; **59**: 2864-2867.
- Dutton MF. Occurrence of mycotoxins in maize in rural areas of South Africa. In: Skudmore KA,eds. *Proc.UK workshop on the occurrence and significance of mycotoxins*. London: MAFF, 1993: 56-63.
- Dutton MF. Fumonisin, mycotoxins of increasing importance: their nature and their effects. *Pharmacol & Therapeut* 1996; **70** (2): 61-137.
- Dutton MF and Kinsey A. Occurrence of mycotoxin in cereals and animal feedstuffs in Natal, South Africa 1994. *Mycopath*, 1995; **131**: 31-36.
- Edrington TS, Kampsholtzapple CA, Harvey RB, Kubena LF, Elissalde MH and Rottinghaus GE. Acute hepatic and renal toxicity in lambs dosed with fumonisin-containing culture material. *J An Sci* 1995; **73**: 508-515.
- Espada Y, Ruiz de Gopegui, R, Cuadradas C and Cabanes FJ. Fumonisin mycotoxicosis in broilers. Weights and serum chemistry modifications. *Avian Dis* 1994; **38**: 454-560.
- Espada Y, Ruiz de Gopegui R, Cuadradas C and Cabanes F.J. Fumonisin mycotoxicosis in broilers: plasma proteins and coagulation modifications. *Avian Dis* 1997; **41**(1): 73-79.
- Fadl-Allah E, S M, Goth R and Bean G. Production of fumonisins B₁, B₂ and B₃ by *Fusarium proliferatum* isolated from rye grains. *Mycotoxin Res* 1997; **13**: 43-46.

- Fazekas B. and Tothe HE. Incidence of fumonisin B₁ in maize cultivated in Hungary. *Magyar Allatorvosok Lapja* 1995; **50**: 515-518.
- Ferguson SA, Omer VE, Kwon OS, Holson RR, Houston RJ, Rottinghaus GE and Slikker W Jr Prenatal fumonisin (FB₁) treatment in rats results in minimal maternal or offspring toxicity. *Neurotoxicol* 1997; **18** (20): 561-569.
- Fields SJ, Vainder Livshits G., Merlob P and Sirotta L. Obesity and the risk of toxemia of pregnancy. *Annals of Human Biol* 1994; **23**(5): 353-362.
- Fincham JE, Marasas WFO., Taljaard JJF et al. Atherogenic effects in a non-human primate of *Fusarium moniliforme* cultures added to a carbohydrate diet. *Atheros* 1992; **94**: 13-25.
- Floss JL, Casteel SW, Johnson GC, Rottinghaus GE, and Krause GF. Developmental toxicity of fumonisin in Syrian hamsters. *Mycopath* 1994; **128**: 33-38.
- Gelderblom WCA, Marasas WFO, Jaskiewicz K, Combrinck S and Van Schalwyk DJ. Cancer promoting potential of different strains of *Fusarium moniliforme* in a short term cancer initiation/promotion assay. *Carcinog* 1988; **9**: 1405-1409.
- Gelderblom CA, Kriek NPJ, Marasas WFO, and Thiel PG. Toxicity and carcinogenicity of the *Fusarium moniliforme* metabolite, fumonisin B₁ in rats. *Carcinog* 1991; **12**: 1247-1251.
- Gelderblom WCA, Marasas WFO, Vleggaar R, Thiel, PG and Cawood ME. Fumonisin: isolation, chemical characterisation and biological effects. *Mycopath* 1992; **117**: 11-16.
- Gelderblom WCA, Snyman SD, van der Westhuizen L and Marasas WFO. Mitoinhibitory effect of fumonisin B₁ on rat hepatocytes in primary cultures. *Carcinog* 1995; **16**: 625-631.
- Gelderblom WC, Snyman SD, Abel S et al. Hepatotoxicity and carcinogenicity of the fumonisins in rats: a review regarding mechanistic implications for establishing risk in humans. *Adv Expt Med & Biol* 1996A; **393**: 279-96.
- Gelderblom WC, Snyman SD, Lebepe-Mazur S, Van der Westhuizen L, Kriek NP. and Marasas WF. The cancer-promoting potential of fumonisin B₁ in rat liver using diethylnitrosamine as a cancer initiator. *Canc Lett* 1996B; **109**(1,2): 101-108.
- Gelderblom WCA, S CM, Abel S, Snyman SD, Van der Westhuizen L, Hubbs WW and Swanevelder S. Effect of fumonisin B₁ on the levels and fatty acid composition of selected lipids in rat liver in vivo. *Food Chem Toxicol* 1997; **35**: 647-656.

- Goel S, Schumacher J, Lenz SD and Kemppainen BW. Effects of *Fusarium moniliforme* isolates on tissue and serum sphingolipid concentration in horses. *Vet Human Toxicol* 1996; **38**(4): 265-270.
- Gross SM, Reddy RV, Rottinghaus GE, Johnson G and Reddy CS. Developmental effects of fumonisin B₁-containing *Fusarium moniliforme* culture extracts in CD1 mice. *Mycopath* 1994; **128**: 111-118.
- Guzman RE, Casteel S.W, Rottinghaus GE and Turk JR. Chronic consumption of fumonisins derived from *Fusarium moniliforme* culture material: clinical and pathologic effects in swine. *J Vet Diagn Invest* 1997A; **9** (2): 216-218.
- Guzman RE, B K, Casteel SW, Turk J and Rottinghaus G. Dietary *Fusarium moniliformin* culture material induces *in vitro* tumor necrosis factor alpha like activity in the sera of swine. *Immunopharm and Immunotoxicol* 1997B; **19**: 279-289.
- Gurel SA and Gurel H. Early development of Hellp syndrome associated with eclampsia: a case report. *European J of Obstet & Gynec & Reprod Biol* 1998; **76** (2): 241-243.
- Haliburton JC, Vesonder RF, Lock TF and Buck WB. Equine leucoencephalomalacia (ELEM): a study of *Fusarium moniliforme* as an etiological agent. *Vet Human Toxicol* 1979; **21**: 348-351.
- Halim A, Bhuiyan AB, Azim FA, Khatun S, Kanayama N, Maradny el E, Maehara K, Hiroshi K and Terao T. Blood coagulation and fibrinolysis in eclamptic patients and their correlation with the clinical signs. *Gynec & Obstet Investigation* 1995; **39** (2): 97-102.
- Hall JO, Javed T, Bennett GA and Richard JL. Serum vitamin A reduction in broiler chicks on feed amended with *Fusarium proliferatum* culture material or fumonisin B₁ and moniliformin. *J Vet Diagnost Invest* 1995; **7**: 416-418.
- Hammer P, B A, and White HG. Carry over fumonisin B₁ into the milk of lactating cows. *Milchwissenschaft*. 1996; **51**: 691-695.
- Handwerker SM, Altura BT and Altura BM. Ionized serum magnesium and potassium levels in pregnant women with pre-eclampsia and eclampsia. *J Reprod Med* 1995; **40** (3): 201-208.
- Harrison LR, Colvin BM, Greene JT, Newman LE and Cole JR. Pulmonary edema and hydrothorax in swine produced by fumonisin B₁, a toxic metabolite of *Fusarium moniliforme*. *J Vet Diagn Invest* . 1990; **2**: 217-221.
- Haschek WM, Motelin G, Ness DK., Harlin KS, Hall WF, Vesonder R, Peterson R. and Beasley VR. Characterisation of fumonisin toxicity in orally and intravenously dosed swine. *Mycopath* 1992; **117**: 83-96.

- Hines HB, Brueggemann EE, Holcom M and Holder CL. Fumonisin B₁ analysis with capillary electrophoresis-electrospray ionization mass spectrometry. *Rapid Comm Mass Spec* 1995; **9**: 519-524.
- Hlywka JJ, B MM, and Bullerman LB. The use of the chick embryo screening tests and brine shrimp bioassay to assess the toxicity of fumonisin B₁ mycotoxin. *Food Chem Toxicol* 1997; **35**: 991-999.
- Holcomb M., Thompson HC and Hankins LJ. Analysis of fumonisin B₁ in rodent feed by gradient elution HPLC using precolumn derivatization with FMOF and fluorescence detection. *J Agric Food Chem* 1993B; **41**: 764-767.
- Holme DJ and Peck H. Analytical Biochemistry. New York: Wiley and Sons, 1994.
- Hopmans EC and Murphy PA, Detection of fumonisins B₁, B₂ and B₃ and hydrolyzed fumonisin B₁ in corn-containing foods. *J Agric Food Chem* 1993; **41**: 1655-1658.
- Howerth EW, Wyatt RD and Hayes DA. Equine leucoencephalomalacia in white tailed deer from North Carolina. *J Wildlife Dis* 1989; **25**: 384-387.
- Huang C, Dickman M., Henderson G. and Jones C. Repression of protein kinase C and simulation of cyclic AMP response elements by fumonisin, a fungal encoded toxin which acts as a carcinogen. *Cancer Res* 1995; **55**: 1655-1659.
- Ito Y, Niwa H, Ando T, Yasuda T and Yanagi T. Clinical and neuroradiological studies of eclampsia-cerebral vasospasm and relation to the brain edema. *Rinsho Shinkeigaku-Clin Neurol* 1995; **35**(4): 358-367.
- Jackson LS, K SK, Fingerhut DD, De Vries JW and Bullerman LB. Effects of baking and frying on the fumonisin B₁ content of corn-based foods. *J Agric Food Chem* 1997; **45**: 4800-4805.
- Jackson MA and Bennett GA.. Production of fumonisin B₁ by *Fusarium moniliforme* NRRL 13616 in submerged culture. *Appl Environ Microbiol* 1990; **56**: 2296-2298.
- Jaskiewicz K, Marasas WFO and Taljaard JJF. Hepatitis in vervet monkeys caused by *Fusarium moniliforme*. *J Comp Path* 1987; **97**: 281-291.
- Javed T, Richard JL, Bennett GA, Dombrink-Kurtzman MA, Cote LM. and Buck WB. Mortality in broiler chicks on feed amended with *Fusarium proliferatum* culture materials or with purified fumonisin B₁ and moniliformin. *Mycopath* 1993; **123**: 171-184.
- Jendryczko A and Tomala J. The total free radical trapping ability of blood plasma in eclampsia. *Zentralblatt fur Gynakologie* 1995; **117**(3): 126-129.
- Josephs JL, Detection and characterization of fumonisin mycotoxins by liquid

- chromatography/electrospray ionization using ion trap and triple quadrupole mass spectrometry. *Rapid Comm Mass Spect* 1996; **10**: 1333-1334.
- Julian AM, Wareing PW, Phillips SI, Medlock VF, MacDonald MV and del Rio LE. Fungal contamination and selected mycotoxins in pre-and post-harvest maize in Honduras. *Mycopath* 1995; **129**: 5-16.
- Katta SK, Cagampang AE, Jackson LS and Bullerman LB. Distribution of *Fusarium* molds and fumonisins in dry-milled corn fractions. *Cereal Chem* 1997; **74**: 858-863.
- Kellerman TS, Marasas WFO, Pienaar JG and Naude TW. A mycotoxicosis of equidae caused by *Fusarium moniliforme*. *Onderstepoort J Vet Res* 1972; **39**: 205-208.
- Kellerman TS, Coetzer JAW and Naude TW. *Plant poisonings and mycotoxicoses of livestock in southern Africa*. Oxford University Cape Town. 75-78.
- Kellerman TS, Marasas WFO, Thiel PG, Gelderblom WCA, Cawood M and Coetzer JAW. Leucoencephalomalacia in two horses induced by oral dosing of fumonisin B₁. *Onderstepoort J Vet Res* 1990; **57**: 269-275.
- Khatun S, Kanayama N, Hossain B, Maradny el E, Kobayashi T, Jahan S, Bhuiyan AB and Tereo T. Increased concentrations of plasma epinephrine and norepinephrine in patients with eclampsia. *European J of Obstet & Gynec & Reprod Biol* 1997; **74(1)**: 103-109.
- Korfmacher WA, Chiarelli MP, Lay Jr JO, Bloom J, Holcomb M. Characterization of the mycotoxin fumonisin B₁: comparison of thermospray, fast-atom bombardment and electrospray mass spectrometry. *Rapid Comm Mass Spect* 1991; **5**: 463-468.
- Knasmuller S, B N, Kassie F, Mersch-Sundermann V, Gelderblom WC, Zohrer E, and Eckl PM. Genotoxin effects of three *Fusarium* mycotoxins, fumonisin B₁ moniliformin and vomitoxin in bacteria and primary cultures of rat hepatocytes. *Mutat Res* 1997; **391**: 39-48.
- Kriek NPJ, Kellerman TS and Marasas WFO. A comparative study of the toxicity of *Fusarium verticillioides* to horses, primates, pigs, sheep and rats. *Onderstepoort J Vet Res* 1981; **48**: 129-131.
- Kubena LF, E TS, Harvey RB, Buckley SA, Phillips TD, Rottinghaus GE, and Caspers HH. Individual and combined effects of fumonisin B₁ present in *Fusarium moniliforme* culture material and T-2 toxin or deoxynivalenol in broiler chicks. *Poult Sc* 1997A; **76**: 1239-1247.
- Kubena LF, E TS, Harvey RB, Phillips TD, Sarr AB, and Rottinghaus GE. Individual and combined effects of fumonisin B₁ present in *Fusarium moniliformin* culture

- material and diacetoxyscirpenol or ochratoxin A in turkey poult. *Poult Sc* 1997B; **76**: 256-264.
- Kwon OS, Schmued LC and Slikker W Jr. Fumonisin B₁ in developing rats alters brain sphinganine levels and myelination. *Neurotoxicol* 1997; **18**(2): 571-579.
- LaBorde JB, Terry KK, C HP, Chen JJ, Collins TFX, Shackelford ME and Hansen DK. Lack of embryotoxicity of fumonisin B₁ in New Zealand white rabbits. *Fund and Appl Toxicol* 1997; **40**: 120-128.
- Lebepe-Mazur S, Wilson T and Hendrich S. *Fusarium proliferatum* fermented corn stimulates development of placental glutathione S-transferase-positive altered hepatic foci in female rats. *Vet Human Toxicol* 1995A; **37**: 39-45.
- Ledoux DR, B AJ and Rottinghaus GE. Effects of feeding *Fusarium moniliforme* culture material containing known levels of fumonisin B₁ in the young turkey poult. *Poult Sc* 1996; **75**: 1472-1478.
- Li J, Sun J and Lu H. Determination of serum free amino acids and ammonia in pregnant women with severe pregnancy induced hypertension. *Chung hua Fu Chan Ko Tsa Chih (Chinese J of Obstet & Gynec)* 1996; **31**(8): 468-470.
- Logrieco A, Moretti A, Bottalico A. and Corda P. Occurrence and toxigenicity of *Fusarium proliferatum* from preharvest maize ear rot and associated mycotoxins in Italy. *Plant Dis* 1995; **79**: 727-731.
- Lu Z, D WR, Hopmans EC, Prisk V, Cunnick JE, Murphy PA, and Hendrich S. Reaction with fructose detoxified fumonisin B₁ while stimulation liver-associated natural killer cell activity in rats. *J Agric Food Chem* 1997; **45**: 803-809.
- Maharaj B and Moodley J. Management of hypertension in pregnancy. *Obstet & Gynec Survey CME* 1994; **12** (12): 1581-1589.
- Manfredi M, Beltramello A, Bongiovanni LG, Polo A, Pistoia L and Rizzuto, N. Eclamptic encephalopathy: imaging and pathogenetic considerations. *Acta Neurologica Scandinivica* 1997; **96**(5): 277-282.
- Maragos CM and Richard JL. Quantitation and stability of fumonisin B₁ and B₂ in milk *J Assoc of Anal Chem Internat* 1994; **77**: 1162-1167.
- Maragos CM. Capillary zone electrophoresis and hplc for the analysis of fluorescein isothiocynatae-labeled fumonisin B₁. *J Agric Food Chem* 1995; **43**: 390-394.
- Maragos CM. Detection of the mycotoxin fumonisin B₁ by a combination of immunofluorescence and capillary electrophoresis. *Food and Agric Immunol* 1997; **9**: 147-157.

- Marasas WFO, Kellerman TS, Pienaar JG and Naude TW. Leukoencephalomalacia: A mycotoxicosis of equidae caused by *Fusarium moniliforme*. *Onderstepoort J Vet Res* 1976; **43**: 113-112.
- Marasas WFO, van Rensburg SJ and Mirocha CJ. Incidence of *Fusarium* species and the mycotoxins, deoxynivalenol and zearalenone in corn produced in esophageal cancer areas in Transkei. *J Agric Food.Chem* 1979; **27**: 1108-1112.
- Marasas WFO, Kriek NPJ, Fincham JE and van Rensburg SJ. Primary liver cancer and oesophageal basal cell hyperplasia in rats caused by *Fusarium moniliforme*. *Int J Cancer* 1984; **34**: 383-387.
- Marasas WFO, Kellerman TS, Gelderblom WCA, Coetzer JAW, van den Lugt JJ. Leukoencephalomalacia in a horse induced by fumonisin B₁ isolated from *Fusarium moniliforme*. *Onderstepoort J Vet Res* 1988; **55**: 197-203.
- Marasas WFO, Thiel PG, Gelderblom WCA, Shephard GS, Sydenham GS and Rheeder JP. Fumonisin produced by *Fusarium moniliforme* in maize: foodborne carcinogens of pan African importance. *Afri Newslett Occup Health Saf Supp* 1993 ; **2**: 11-18.
- Marijanovic DR, Holt P, Norred WP, Bacon CW, Voss KA and Stancel PC. Immunosuppressive effect of *Fusarium moniliforme* corn cultures in chickens. *Poult Sc* 1991; **70**: 1895-1901.
- Martinova EA and Merrill AH. Fumonisin B₁ alters sphingolipid metabolism and immune function in BALB/c mice: immunological responses to fumonisin B₁. *Mycopath* 1995; **130**: 163-170.
- McCowan LM, Buist RG, North RA and Gamble G. Perinatal morbidity in chronic hypertension. *British J of Obstet & Gynec* 1996; **103**(2): 123-129.
- Mclean Michelle. The phytotoxicity of *Fusarium* metabolites: an update since 1989. *Mycopath* 1996; **133**: 163-179.
- Melcion D, C B, and Richard-Molard D. Study of biosynthesis of fumonisins B₁, B₂ and B₃ by different strains of *Fusarium moniliforme*. *Letters in Appl Biol* 1997; **24**: 301-305.
- Meredith F, B C, Norred W and Plattner R. Purification of fumonisin B₂ isolated from rice culture. *Agric Food Chem* 1997; **45**: 3143-3147.
- Merrill AH, Wang E, Mullins RE, Jamison WCL, Nimkar S. and Liotta DC. Quantitation of free sphingosine in liver by high performance liquid chromatography. *Anal Biochem* 1988; **171**: 373-381.
- Merrill AH, Wang E, Vales TR., Smith ER, Schroeder JJ, Menaldino DS, Alexander C,

- Crane HM, Xia J, Liotta DC, Meredith FI, and Riley RT. Fumonisin toxicity and sphingolipid biosynthesis. *Adv Expt Med & Biol* 1996; **392**: 297-306.
- Merrill AH, van Echten G, Wang E and Sandhoff K. Fumonisin B₁ inhibits sphingosine N acyltransferase and de novo sphingolipid biosynthesis in cultured neurons in situ. *J Biol Chem* 1993A; **268**: 27299-27306.
- Merrill AH, Lingrell S, Wang E, Nikolova-Karakashian M, Vales TR and Vance DE. Sphingolipid biosynthesis de novo by rat hepatocytes in culture. Ceramide and sphingomyelin are associated with, but not required for very low density lipoprotein secretion. *J Biol Chem* 1995; **270**: 13834-13841.
- Merrill AH, S EM, Wang E, Dillehay DL, Rice LG, Meredith F and Riley RT. Importance of sphingolipids and inhibitors of sphingolipid metabolism as components of animal diet. *J Nutrition* 1997; **127**: 830S-833S.
- Miller JD, Savard ME and Rapior S. Production and purification of fumonisins from a stirred jar fermenter. *Nat Toxins* 1994; **2**: 354-359.
- Mirocha CJ, Gilchrist DG, Shier WT, Abbas HK, Wen Y and Vesonder RF. AAL toxins, fumonisins (biology and chemistry) and host specificity concepts. *Mycopath* 1992; **117**: 47-56.
- Moodley J. Hypertension in pregnancy. *Obstet and Gynec Survey CME* 1991; **9** (1): 72-80.
- Morgan MK, Schroeder JJ, Rottinghaus GE, Powell DC, Bursian SJ and Aulerich RJ. Dietary fumonisins disrupt sphingolipid metabolism in mink and increase the free sphinganine to sphingosine ratio in urine but not in hair. *Vet Human Toxicol* 1997; **39**: 34-36.
- Murphy PA., Rice LG and Ross PF. Fumonisin B₁, B₂ and B₃ content of Iowa, Wisconsin and Illinois corn and corn screenings. *J Agric Food Chem* 1993; **41**: 263-266.
- Naicker T, Randeree IG, Moodley J, Khedun SM., Ramsaroop R. and Seedat YK. Correlation between histological changes and loss of anionic charge of the glomerular basement membrane in early-onset pre-eclampsia. *Nephron* 1997; **75**(2): 201-207.
- Nelson PE, Plattner RD, Shackelford DD and Desjardins AE. Fumonisin B₁ production by *Fusarium* species other than *F.moniliforme* in section Liseola and by some related species. *Appl Environ Microbiol* 1992; **58**: 984-989.
- Nelson PE, Desjardins AE and Plattner RD. Fumonisins, mycotoxins produced by *Fusarium* species: biology, chemistry and significance. *Ann Rev Phytopath* 1993; **31**:233-252.

- Norred W.P, Bacon C.W, Porter JK and Voss KA. Inhibition of protein synthesis in rat primary hepatocytes by extracts of *Fusarium moniliforme* -contaminated corn *Food.Chem Toxicol* 1990; **28**: 89-94.
- Norred WP, Plattner RD and Chamberlain WD. Distribution and excretion of (¹⁴C) fumonisin B₁ in male Sprague-Dawley rats. *Nat Toxin* 1993; **1**: 341-346.
- Norred WP, Plattner RD, Dombrink Kurtzman MA, Meredith FI. and Riley RT. Mycotoxin-induced elevation of free sphingoid bases in precision-cut rat liver slices. Specificity of the response and structure -activity relationships. *Toxicol & Appl Pharm* 1997; **147**: 63-70.
- Norred WP, Voss KA., Riley RT and Plattner RD. Fumonisin toxicity and metabolism studies at the USDA-Fumonisin toxicity and metabolism. *Adv Expt Med & Biol* 1996; **392**: 225-236.
- Ozan H, Esmer A, Kolsal N, Copur OU and Ediz B. Plasma ascorbic acid level and erythrocyte fragility in pre-eclampsia and eclampsia. *European J Obstet Gynec & Reprod Bio.* 1997 ;**71**(1): 35-40.
- Oswailer GD, Ross PF, Wilson TM, Nelson PE, Witte ST, Carson TL, Rice LG and Nelson HA. Characterization of epizootic of pulmonary edema in swine associated with fumonisin in corn screenings. *J Vet Diag Invest* 1992; **4**: 53-59.
- Oswailer GD, Kehrli ME, Stabel JR, Thursron JR, Ross PF and Wilson TM. Effects of fumonisin-contaminated corn screenings on growth and health of feeder calves. *J An Sci* 1993; **71**: 459-466.
- Patel S, H CM, Winterton AGM and Gleadle AE. Surveillance of fumonisins in UK maize-based foods and other cereals. *Food Add Contam* 1997; **14**: 187-191.
- Pellegrin F, Laurent D, Kohler F, Sauviat MP and Platzer N. Corn fusariosis associated with equine leukoencephalomalacia. *Microbiol Alimen Nutrit* 1990; **8**: 249-256.
- Pestka JJ, Azcona-Olivera JI, Plattner RD, Minervini F, Doko, MB and Visconti A. Comparative assessment of fumonisin in grain based foods by ELISA GC-MS and HPLC. *J Food Protection* 1994; **57**: 169-172.
- Pineiro MS, S GE, Scott PM, Lawrence GA and Stack ME. Fumonisin levels in Uruguayan corn products. *J Assoc Off Anal Chemists Internat* 1997; **80**: 825-828.
- Pittet A, Parisod V and Schellenberg M. Occurrence of fumonisins B₁ and B₂ in corn-based products from the Swiss market. *J Agric Food Chem* 1992; **40**: 1352-1354.
- Plattner RD, Norred WP, Voss KA, Peterson R, Shachelford DD. and Weislander DA. A method of detection of fumonisin in corn samples associated with field cases of equine leukoencephalomalacia. *Mycologia* 1990; **82**: 698-702.

- Plattner RD, Ross PF, Reagor J, Stedelin J and Rice LG. Analysis of corn and cultured corn for fumonisin B₁ by HPLC and GC/MS by four laboratories. *J Vet Diag Invest* 1991; **3**: 357-358.
- Plattner RD and Shackelford DD. Biosynthesis of labelled fumonisins in liquid cultures. *Mycopath* 1992; **117**: 17-22.
- Plattner RD, Weisleder D, Shackelford DD, Peterson R and Powell RG. A new fumonisin from solid cultures of *Fusarium moniliforme*. *Mycopath* 1992; **117**: 23-28.
- Plattner RD. HPLC/MS analysis of *Fusarium* mycotoxins Fumonisin and Deoxynivalenol. In *proc.: Advances in Detection Methods for Fungal and Algal Toxins* Salisbury Cove, Satellite Workshop to the Gordon Conference on Mycotoxins and Phycotoxins, 1999:1-8.
- Plumlee KH and Galey FD. Neurotoxic mycotoxins: a review of fungal toxins that cause neurological disease in large animals. *J Vet Internal Med* 1994; **8**: 49-54.
- Poche GK, Powell RG, Plattner RD and Weislder D. Relative stereochemistry of fumonisin B₁ at C-2 and C-3. *Tet Letts* 1994; **35**: 7707-7710.
- Prelusky DB, Trenholm HL and Savard ME. Pharmacokinetic fate of ¹⁴C-labelled fumonisin B₁ in swine. *Nat Toxins* 1994; **2**: 73-80.
- Price WD, Lovell RA and McChesney DG. Naturally occurring toxins in feedstuff: center for Veterinary Medicine Perspective. *J An Sci* 1993; **71**: 2556-2562.
- Qureshi MA and Hagler WM. Effects of fumonisin B₁ exposure on chicken macrophage functions in vitro. *Poult Sc* 1992; **71**: 104-112.
- Ramasamy S, Wang E, Hennig B. and Merrill A.H. Fumonisin B₁ alters sphingolipid metabolism and disrupts the barrier function of endothelial cells in culture. *Toxicol Appl Pharmacol* 1995; **133**: 343-348.
- Randeree IG, Czarnocki A, Moodley J, Seedat YK and Naiker IP. Acute renal failure in pregnancy in South Africa. *Renal Fail* 1995; **17(2)**: 147-153.
- Reddy RV, Johnson G, Rottinghaus GE, Casteel SW and Reddy CS. Developmental effects of fumonisin B₁ in mice. *Mycopath* 1996; **134(3)**: 161-166.
- Restum JC, Bursian SJ, Millerick M., Render JA, Merrill AH, Wang E, Rottinghaus GE and Aulerich RJ. Chronic toxicity of fumonisins from *Fusarium moniliforme* culture material (M-1325) to mink. *Arch Environ Contam & Toxicol* 1995; **29**: 545-550.
- Rheeder JP, Marasas WFO, Thiel PG, Sydenham EW, Shephard GS. and Van Schalkwyk DJ. *Fusarium moniliforme* and fumonisins in corn in relation to human esophageal

- cancer in Transkei. *Phytopath* 1992; **82**: 353-357.
- Riley RT, An S, Showker JL. Alteration of tissue and serum sphinganine to sphingosine ratio: an early biomarker of exposure to fumonisin containing feeds in pigs. *Toxicol Appl Pharm* 1993; **118**: 105-112.
- Riley RT, Hinton DM., Chamberlain WJ, Bacon CW, Wang E, Merrill AH. and Voss KA. Dietary fumonisin B₁ induces disruption of sphingolipid metabolism in Sprague-Dawley rats: a new mechanism of nephrotoxicity. *J Nutrition* 1994; **124**: 594-603.
- Riley RT, Wang E, Schroeder JJ. Evidence for disruption of sphingolipid metabolism as a contributing factor in the toxicity and carcinogenicity of fumonisins. *Nat Toxins* 1996; **4**(1): 3-15.
- Riley RT, Showker JL, Owens DL and Ross PF. Disruption of sphingolipid metabolism and induction of equine leukoencephalomalacia by *Fusarium proliferatum* culture material containing fumonisin B₂ or B₃. *Environ Toxicol & Pharmacol* 1997; **3**: 221-228.
- Ritieni A, M A, Logrieco A, Bottalico A, Randazzo G, Monti SM, Ferracane R and Fogliano V. Occurrence of fusaproliferin fumonisin B₁ and beauvericin in maize from Italy. *J Agric Food Chem* 1997; **45**: 4011-4016.
- Rose FR. Esophageal cancer in the Transkei: 1955-69. *J Nat Cancer Inst* 1973; **51**: 7-16.
- Ross P, Rice LG, Plattner RD, et al. Concentrations of fumonisin B₁ in feeds associated with animal health problems. *Mycopath* 1991; **114**: 129-135.
- Ross PF, Rice LG, Osweiler GD, Nelson PE, Richard JL and Wilson TM. A review and update of animal toxicoses associated with fumonisin contaminated feeds and production of fumonisins by *Fusarium* isolates. *Mycopath* 1992; **117**: 109-114.
- Rother J, van Echten G, Schwartzmann G and Sandhoff K. Biosynthesis of sphingolipids: dihydroceramide and not sphinganine is desaturated by cultured cells. *Biochem Biophys Res Comm* 1992; **189**: 14-20.
- Rotter BA, T BK, Prelusky DB, Trenholm HL, Stewart B, Miller JD and Savard ME. Response of growing swine to dietary exposure to pure fumonisin B₁ during an eight week period: growth and clinical parameters. *Nat Toxins* 1996; **4**: 42-50.
- Rottinghaus GE, Coatney CE and Minor HC. A rapid sensitive thin layer chromatography procedure for the detection of fumonisin B₁ and B₂. *J Vet Diagn Invest* 1992; **4**: 326-329.
- Rumbeiha WK, and O FW. Fumonisin exposure to Kansans through consumption of corn-based market foods. *Vet Human Toxicol* 1997; **39**: 220-225.

- Sanchis V, Abadias M., Oncins L, Salas N, Vinas I, and Canela, R. Occurrence of fumonisins B₁ and B₂ in corn-based products from the Spanish market. *Appl Environ Microbiol* 1994; **60**: 2147-2148.
- Sanchis V, Abadias M., Oncins L, Sala N, Vinas and Canela R. Fumonisins B₁ and B₂ and toxigenic *Fusarium* strains in feeds from the Spanish market. *Internat J Food Microbiol* 1995; **27**: 37-44.
- Schneider E, Usleber E and Martlbauer E. Rapid detection of fumonisin B₁ in corn based food by competitive direct dipstick enzyme immunoassay enzyme- linked immunofiltration assay with integrated negative control reaction. *J Agric Food Chem* 1995; **43**: 2548-2552.
- Schumacher J, Mullen J, Shelby R, Lenz S, Ruffin DC and Kemppainen BW. An investigation of the role of *Fusarium moniliforme* in duodenitis/proximal jejunitis of horses. *Vet Human Toxicol* 1995; **37**: 39-45.
- Schwartz A, Rapaport E and Hirschberg K and Futerman AH. A regulatory role for sphingolipids in neuronal growth. Inhibition of sphingolipid biosynthesis and degradation have opposite effects on axonal branching. *J Biol Chem* 1995; **270**: 10990-10998.
- Scott PM and Lawrence GA. Stability and problems in recovery of fumonisins added to corn-based foods. *J Assoc Off Anal Chem Internat* 1994; **77**: 541-545.
- Scott PM, Y JM, Lawrence GA and Prelusky DB. Evaluation of enzyme linked immunosorbent assay for analysis of beer for fumonisins. *Food Add Contam* 1997; **14**: 445-450.
- Segal I, Reinach SG and de Beer M. Factors associated with oesophageal cancer in Soweto, South Africa. *Brit J Cancer* 1988; **58**: 681-686.
- Seo JA, K JC and Lee YW. Isolation and characterization of two new type C fumonisins produced by *Fusarium oxysporum*. *J Nat Products* 1996; **59**: 1003-1005.
- Shaarawy M, el Mallah SY and el Yamani AA. Clinical significance of urinary human tissue non-specific alkaline phosphatase (hTNAP) in pre-eclampsia and eclampsia. *Annals of Clin Biochem* 1997; **34**(4):405-411.
- Sharma RP, Dugyala RR and Voss KA. Demonstration of in-situ apoptosis in mouse liver and kidney after short-term repeated exposure to fumonisin B₁. *J Comp Path* 1997; **117**: 371-381.
- Shephard GS, Thiel PG, Sydenham GS, Gelderblom WCA. Quantitative determination of fumonisin B₁ and B₂ by high performance liquid chromatography with fluorescence detection. *J Liq Chromatog* 1990; **13**: 2077-2087.

- Shephard GS, Thiel PG and Sydenham EW. Determination of fumonisin B₁ in plasma and urine by high performance liquid chromatography. *J Chromatog* 1992A; **574**: 299-304.
- Shephard GS, Thiel PG, Sydenham EW, Alberts JF and Gelderblom WCA. Fate of a single dose of the ¹⁴C - labelled mycotoxin fumonisin B₁ rats. *Toxicon* 1992B; **30** : 768-770.
- Shephard GS , Thiel PG, Sydenham GS, Vleggaar R and Alberts JF. Partially hydrolysed metabolites in the faeces of non-human primates. *Food Chem Toxicol* 1994; **32**: 23-29.
- Shephard GS, Thiel PG, Sydenham EW and Alberts JF. Biliary excretion of the mycotoxin fumonisin B₁ in rats. *Food Chem. Toxicol* 1994A; **32**: 489-491.
- Shephard GS, Thiel PG, Sydenham, GS, Alberts JF and Cawood ME. Distribution and excretion of a single dose of the mycotoxin fumonisin B₁ in the non-human primate. *Toxicon* 1994B; **32**: 735-741.
- Shephard GS, van der Westhuizen L, Thiel PG, Gelderblom WC, Marasas WF, van Schalkwyk, DJ. Disruption of sphingolipid metabolism in non-human primates consuming diets of fumonisin-containing *Fusarium moniliforme* culture material. *Toxicon* 1996; **34**(5): 527-34.
- Shetty P, aB, RV. Natural occurrence of fumonisin B₁ and its co-occurrence with aflatoxin B₁ in Indian sorghum, maize and poultry feeds. *J Agric Food Chem* 1997; **45**: 2170-2173.
- Smith GW, C PD, and Haschek WM. Cardiovascular response to short term fumonisin exposure in swine. *Fundamental and Appl Toxicology* 1996; **33**: 140-148.
- Solfrizzo M., Avantaggiato G and Visconti A. Rapid method to determine sphinganine/sphingosine in human and animal urine as a biomarker for fumonisin exposure. *J of Chromatog.B, Biomed Sc & Applications* 1997; **692**: 87-93.
- Soo LU, Yur LM, Sop SK, Sik MY, Min CC, and Ueno Y. Production of fumonisin B₁ and B₂ by *Fusarium moniliforme* isolated from Korean corn kernels for feed. *Mycotoxin Res* 1994; **10**: 67-72.
- Srivastava M, Bali S, Pandey J, Nayar V and Talib VH. Pregnancy induced hypertension and antithrombin-111. *Indian J of Path & Micribiol* 1995; **38**(3): 257-260.
- Stack ME, Eppley RM. Liquid chromatographic determination of fumonisin B₁ and B₂ in corn and corn products. *J Assoc Off Anal Chem* 1992; **75**: 834-837
- Suzuki CAM, Hierlihy L, Barker M., Curran I, Mueller R and Bondy GS. The effects of fumonisin B₁ on several markers of nephrotoxicity in rats. *Toxicol & Applied*

Pharmacol 1995; **133**: 207-214.

Sydenham EW, Thiel PG, Marasas WFO, Shephard GS, van Schalkwyk DJ, Koch KR. Natural occurrence of some *Fusarium* mycotoxins in corn from low and high esophageal cancer prevalence areas of the Transkei, South Africa. *J Agric Food Chem* 1990; **38**: 1900-1903.

Sydenham EW, Shephard GS, Thiel PG, Marasas WFO, Stockenstrom S. Fumonisin contamination of commercial corn-based human foodstuffs. *J Agric Food Chem* 1991; **39**: 2014-2018.

Sydenham EW, Marasas WFO, Shephard GS, Thiel PG. and Hirooka EY. Fumonisin concentrations in Brazilian feeds associated with field outbreaks of confirmed and suspected animal mycotoxicoses. *J Agric Food Chem* 1992A; **40**: 994-997.

Sydenham EW, Shephard GS and Thiel PG. Liquid chromatographic determination of fumonisins B₁, B₂, and B₃ in foods and feeds. *J Assoc Off Anal Chem Internat* 1992B; **75**: 313-318.

Sydenham EW, Thiel PG, Shephard GS, Koch KR and Hutton T. Preparation and isolation of the partially hydrolyzed moiety of fumonisin B₁. *J Agric Food Chem* 1995; **43**: 2400-2405.

Sydenham EW, Shephard GS, Stockenstrom S, Rheeder JP, Marasas WFO and Van der Merwe MJ. Production of fumonisin B₁ analogues and related compounds by *Fusarium globosum*, a newly described species from corn. *J Agric Food Chem* 1997; **45**: 4004-4010.

Thiel PG, Shephard GS, Sydenham EW, Marasas WFO., Nelson PE and Wilson TM. Levels of fumonisins B₁ and B₂ in feeds associated with confirmed cases of equine leukoencephalomalacia. *J Agric Food Chem* 1991; **39**: 109-111.

Thiel PG, Sydenham EW, Shephard GS and van Schalkwyk DJ. Study of the reproducibility characteristics of a liquid chromatographic method for the determination of fumonisins B₁ and B₂ in corn IUPAC collaborative study. *J Assoc Off Anal Chem Internat* 1993; **76**: 361-366.

Trucksess MW, Stack ME, Allen S and Barrion N. Immunoaffinity column coupled with liquid chromatography for determination of fumonisin B₁ in canned and frozen sweet corn. *J Assoc off Anal Chem Internat* 1995; **78**: 705-710.

Tryphonas H, Bondy G, Miller JD, Lacroix F, Hodgen M, McGuire P, Fernie S, Miller D. and Hayward S. Effects of fumonisin B₁ on the immune system of Sprague-Dawley rats following a 14-day oral (gavage) exposure. *Fund & Applied Toxicol* 1997; **39**: 53-59.

Tseng TC and Liu CY. Occurrence of fumonisin B₁ and B₂ in corn-based foodstuffs in

- Taiwan market. *Mycopath* 1997; **137**: 57-61.
- Ueno Y, Aoyama S, Suglaru Y, Wang DS, Lee US, Hirooka EY, Hara S, Karki T, Chen G and Yu SZ. A limited survey of fumonisins in corn and corn-based products in Asian countries. *Mycotoxin Res* 1993; **9**:27-34.
- Ueno Y, Hjima K, Wang SD, Sugiura Y, Sekijima M, Tanaka T Chen C, Yu SZ. Fumonisin as a possible contributory risk factor for primary liver cancer : a 3 year study of corn harvested in Haimen, China by HPLC and Elisa. *Food Chem Toxicol* 1997; **35**: 1143-1150.
- Usleber E, Straka M and Terplan G. Enzyme immunoassay for fumonisin B₁ applied to corn based foods. *J Agric Food Chem* 1994; **42**: 1392-1396.
- Van den Elzen HJ, Wladimiroff JW, Overbeek TE, Morris CD and Grobbee DE. Calcium metabolism, calcium supplementation and hypertensive disorders of pregnancy. *European J of Obstet, Gynec & Reprod Biol* 1995; **59**(1): 5-16
- Van den Elzen HJ, Wladimiroff JW, Cohen-Overbeek TE, de Bruijn AJ and Grobbee DE. Serum lipids in early pregnancy and risk of pre-eclampsia. *British J of Obstet & Gynec* 1996; **103**(2): 117-122..
- Vasiljevic N, Vasiljevic M and Plecas D. The role of nutritional factors in pre-eclampsia and eclampsia. *Srpski Arhiv Za Celokupno Lekarstvo* 1996; **124**(5-6): 156-159
- Vesonder R, Peterson R, Plattner R. and Weislander D. Fumonisin B₁ isolation from corn culture and purification by high performance liquid chromatography. *Mycotoxin Res* 1990; **6**: 85-88.
- Vleggaar R. Mycotoxins world first for S.Africa-fatal disease may be eradicated. *Scientiae* 1989; **30**(2): 17-20.
- Voss KA, Plattner RD, Riley RT, Meredith FI and Norred WP. *In vivo* effects of fumonisin B₁ producing and fumonisin B₁ non-producing *Fusarium moniliforme* isolates are similar: fumonisin B₂ and B₃ cause hepato and nephrotoxicity in rats. *Mycopath* 1998B; **141**: 45-58.
- Voss KA, Bacon CW, Norred, et al. Studies of the reproductive effects of *Fusarium moniliforme* culture material in rats and the biodistribution of ¹⁴C fumonisin in pregnant rats. *Nut & Health* 1998A; **12**(2): 134-135.
- Vudathala DK, Prelusky DB, Ayroud M., Trenholm HL and Miller JD. Pharmacokinetic fate and pathological effects of ¹⁴C-fumonisin B₁ in laying hens. *Nat Toxins* 1994; **2**: 81-88.
- Wang E, Norred WP, Bacon CW, Riley RT and Merrill AH. Inhibition of sphingolipid biosynthesis with fumonisin. *J Biol Chem* 1991; **266**: 14480-14490.

- Wang E, Ross F, Wilson TM, Riley RT and Merrill AH. Increases in serum sphingosine and sphinganine and decreases in complex sphingolipids in ponies given feed containing fumonisins, mycotoxins produced by *Fusarium moniliforme*. *J Nutrition* 1992; **122**: 1706-1716.
- Ware GM, Umrigar PP, Carman AS and Kuan SS. Evaluation of fumonitoxin immunoaffinity columns. *Anal Letts* 1994; **27**: 693-715.
- Weibking T, Ledoux DR, Bermudez AJ, Turk JR, Rottinghaus GE, Wang E and Merrill AH. Effects of feeding *Fusarium moniliforme* culture material, containing known levels of fumonisin B₁ on the young broiler chick. *Poult Sc* 1993; **72**: 456-466.
- Weibking T, Ledoux DR, Bermudez AJ and Rottinghaus GE. Individual and combined effects of feeding *Fusarium moniliforme* culture material, containing known levels of fumonisin B₁ and aflatoxin B₁ in the young turkey poult. *Poult Sc* 1994; **73**: 1517-1525.
- Wilkes JG and Sutherland JB. Sample preparation and high-resolution separation of mycotoxins possessing carboxyl groups. *J Chromatog B* 1998; **717**: 135-156.
- Wilkins PA, Vaala WE, Zivotofsky D and Twitchell ED. A herd outbreak of equine leukoencephalomalacia. *Cornell Vet* 1994; **84**: 53-59.
- Wilson BJ and Maronpot RR. Causative fungus agent of leukoencephalomalacia in equine animals. *Vet Rec* 1971; **88**: 484-486.
- Wilson TM, Ross PF, Owens DL, Rice LG, Green SA, Jenkins SJ and Nelson HA. Experimental reproduction of ELEM: a study to determine the minimum toxic dose in ponies. *Mycopath* 1992; **117**: 115-120.
- Witlin AG, Friedman SA, Eggerman RS, Frangieh AY and Sibai BM. Cerebrovascular disorders complicating pregnancy beyond eclampsia. *Am J of Obstet & Gynec* 1997; **176**(6): 1139-1148.
- Wu WD, Li GY, Liu TX and Vesonder RR. The effect of fumonisin B₁ on isolated chondrocytes and on bone formation. *Poult Sc* 1995; **74**: 1431-1436.
- Xie W, M CJ and Chen J. Detection of two naturally occurring structural isomers of partially hydrolysed fumonisin B₁ in corn by on-line capillary liquid chromatography-fast atom bombardment mass spectrometry. *J Agric Food Chem* 1997; **45**: 1251-1255.
- Yamashita A, Yoshizawa T, Aiura Y. *Fusarium* mycotoxins (fumonisins, nivalenol and zearalenone) and aflatoxins from Southeast Asia. *Biosci Biotech Biochem* 1995; **59**: 1804-1807.
- Yang CS. Research on esophageal cancer in China: a review. *Cancer Res* 1980; **40**: 2633-

2644.

Yoshizawa T, Yamashita A and Luo Y. Fumonisin occurrence in corn from high and low risk areas from human esophageal cancer in China. *Appl Environ Microbiol* 1994; **60**: 1626-1629.